<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-151525" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sympathetic Ophthalmia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yan</surname>
            <given-names>Junru</given-names>
          </name>
          <aff>UCLA</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hobbs</surname>
            <given-names>Samuel D.</given-names>
          </name>
          <aff>Wilford Hall Ambulatory Surgical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Junru Yan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samuel Hobbs declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-151525.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Sympathetic ophthalmia is a rare, devastating disease defined as bilateral uveitis following an eye injury.&#x000a0;The condition may result in permanent bilateral vision loss in an otherwise healthy patient with no ocular morbidities. Initial symptoms and the timeline for the onset of symptoms after an injury are highly variable. Therefore, sympathetic ophthalmia must be considered&#x000a0;within the differential&#x000a0;for any presentation of bilateral uveitis. Managing this disease&#x000a0;is&#x000a0;challenging, requiring several immunosuppressants as part of treatment. Sympathetic ophthalmia is an uncommon, systemic uveitis that develops as a granulomatous inflammation in both eyes after an injury or invasive procedure. Typically emerging within the first 12 months post-injury,&#x000a0;the onset can be postponed for several years. This condition is characterized by granulomatous inflammation with distinctive choroidal yellow-white nodules. Early treatment usually involves high doses of corticosteroids, which can elicit a prompt response; however, sustaining the remission often necessitates continuous immunomodulatory agents to curb further flare-ups.</p>
        <p>This&#x000a0;topic&#x000a0;equips clinicians with comprehensive knowledge of sympathetic ophthalmia, including its diverse clinical presentations and management strategies. Through collaborative learning, clinicians understand the importance of early diagnosis and tailored treatment plans to prevent irreversible vision impairment. Interprofessional teamwork enhances patient outcomes by facilitating holistic care and integrating ophthalmological expertise with immunological insights. By fostering effective communication and collaboration among specialists, the course empowers healthcare professionals to deliver timely interventions, optimize treatment regimens, and improve overall prognosis for patients with sympathetic ophthalmia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical features and risk factors associated with sympathetic ophthalmia.&#x000a0;</p></list-item><list-item><p>Differentiate sympathetic ophthalmia from other forms of uveitis based on clinical presentation and history of ocular trauma.&#x000a0;</p></list-item><list-item><p>Screen patients presenting with bilateral uveitis for signs suggestive of sympathetic ophthalmia, utilizing appropriate diagnostic tests.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=151525&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=151525">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-151525.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sympathetic ophthalmia is a rare pathologic process characterized by bilateral uveitis following injury to&#x000a0;1 eye either from surgery or penetrating ocular trauma.<xref ref-type="bibr" rid="article-151525.r1">[1]</xref>&#x000a0;Though this is a rare process,&#x000a0;the condition&#x000a0;is serious&#x000a0;and can&#x000a0;cause blindness in the injured eye (ie, the inciting eye) and the contralateral eye (ie, the sympathizing eye). The onset of symptoms typically occurs within&#x000a0;1&#x000a0;year of injury&#x000a0;but&#x000a0;can&#x000a0;occur up to 66 years&#x000a0;after&#x000a0;the initial injury.<xref ref-type="bibr" rid="article-151525.r2">[2]</xref>&#x000a0;Sympathetic ophthalmia, often called sympathetic uveitis, is an uncommon and severe eye condition triggered by an immune system response. This inflammation impacts both eyes following trauma or surgery to&#x000a0;1 eye, especially when uveal tissue is involved.<xref ref-type="bibr" rid="article-151525.r3">[3]</xref></p>
        <p>The eye experiencing the initial trauma or surgery&#x000a0;is called&#x000a0;the&#x000a0;"inciting"&#x000a0;eye, while the other, affected eye is termed the&#x000a0;"sympathizing"&#x000a0;eye. The onset of symptoms can occur anytime from a few days to many years post-injury, but most cases appear within&#x000a0;1&#x000a0;year of the inciting event. Historically, younger individuals were more frequently affected due to accidental injuries. Still, recent reports suggest an increased occurrence in older adults, possibly linked to the higher rates of ocular surgeries in this demographic.<xref ref-type="bibr" rid="article-151525.r4">[4]</xref>&#x000a0;Sympathetic ophthalmia, although rare, carries a significant risk of causing vision loss in both eyes. The exact pathogenesis of sympathetic ophthalmia is unclear.&#x000a0;The&#x000a0;immune-privileged status of the eye occurs after a penetrating injury and exposure of previously sequestered uveoretinal antigens to the systemic immune system. The resulting inflammation in the eye&#x000a0;is devastating and causes permanent blindness. Therefore, early detection and intervention with immunosuppression are vital.<xref ref-type="bibr" rid="article-151525.r5">[5]</xref></p>
        <p>The clinical presentation can vary, with symptoms typically developing weeks to months after the initial injury. In some cases, the onset&#x000a0;is delayed for years, leading to challenges in diagnosis. Common symptoms include decreased vision, eye redness, pain, and sensitivity to light. Upon examination, ophthalmologists may find signs such as inflammation in the vitreous and anterior chamber, choroidal lesions, and, in some cases, the characteristic Dalen-Fuchs nodules, accumulations of inflammatory cells beneath the retina.<xref ref-type="bibr" rid="article-151525.r6">[6]</xref>&#x000a0;Sympathetic ophthalmia is primarily diagnosed through clinical findings and the history of trauma or surgery to the eye. Ancillary tests such as ocular imaging and laboratory investigations can support the diagnosis but are not definitive. The importance of early detection and treatment cannot&#x000a0;be overstated, as timely management can significantly alter the disease course.<xref ref-type="bibr" rid="article-151525.r7">[7]</xref></p>
        <p>Treatment typically begins with high doses of corticosteroids to suppress the immune response and control inflammation. Due to the chronic nature of sympathetic ophthalmia, many patients require long-term immunosuppression to maintain control of the inflammation and preserve vision.&#x000a0;This&#x000a0;often necessitates the use of steroid-sparing agents like methotrexate, azathioprine, or biologic drugs. The risk factors for developing&#x000a0;this condition include the nature of the trauma, the extent of uveal tissue exposure, and possibly genetic predispositions.<xref ref-type="bibr" rid="article-151525.r8">[8]</xref>&#x000a0;Given&#x000a0;the potential severity, prevention is a&#x000a0;key&#x000a0;aspect of management in ocular trauma and surgery, with meticulous surgical techniques to avoid uveal tissue exposure and prompt, aggressive treatment of any postoperative inflammation. Understanding&#x000a0;sympathetic ophthalmia&#x000a0;has evolved with advances in immunology and ocular imaging yet remains an active research area. Studies continue to seek better ways to predict who is at risk, how to prevent&#x000a0;the development, and how to optimize long-term management to prevent recurrences and preserve vision. Sympathetic ophthalmia&#x000a0;is an enigmatic and potentially devastating condition that encapsulates the intricate interplay between the ocular tissues and the immune system.&#x000a0;The capacity to affect vision dramatically shows the importance of preventive strategies during ocular surgery, the necessity for vigilance in the face of ocular trauma, and the evolving landscape of immunomodulatory therapies in ophthalmology.<xref ref-type="bibr" rid="article-151525.r9">[9]</xref></p>
      </sec>
      <sec id="article-151525.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>First coined by William Mackenzie in 1840, sympathetic ophthalmia refers to bilateral ocular inflammation secondary to unilateral eye trauma or surgery.<xref ref-type="bibr" rid="article-151525.r10">[10]</xref>&#x000a0;Classically,&#x000a0;sympathetic ophthalmia&#x000a0;is defined as a bilateral diffuse granulomatous panuveitis&#x000a0;that presents with mutton fat keratitic precipitates. However, patient presentations of sympathetic ophthalmia may significantly vary in inflammation on presentation. Per the Standardization of Uveitis Nomenclature working group definition in 2021, the diagnosis criteria for sympathetic ophthalmia are as follows: (1) history of unilateral ocular trauma or surgery AND (2) ocular inflammation in both eyes or, if the inciting eye has no view, detectable inflammation in the sympathizing eye AND (3) either anterior uveitis with vitreous inflammation OR panuveitis with choroidal involvement.<xref ref-type="bibr" rid="article-151525.r1">[1]</xref>&#x000a0;Penetrating ocular trauma and vitreoretinal surgeries&#x000a0;cause the highest risk of developing sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r11">[11]</xref>&#x000a0;However, cases of sympathetic ophthalmia have&#x000a0;been reported&#x000a0;with cataract surgery, glaucoma surgery, intravitreal injections,&#x000a0;cyclodestructive&#x000a0;procedures, choroidal melanoma radiation therapy, and pan-retinal photocoagulation.<xref ref-type="bibr" rid="article-151525.r12">[12]</xref><xref ref-type="bibr" rid="article-151525.r13">[13]</xref><xref ref-type="bibr" rid="article-151525.r14">[14]</xref><xref ref-type="bibr" rid="article-151525.r15">[15]</xref></p>
        <p>
<bold>Triggering Events</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Trauma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Surgical intervention</p>
          </list-item>
          <list-item>
            <p>Other ocular pathologies&#x000a0;<xref ref-type="bibr" rid="article-151525.r16">[16]</xref><xref ref-type="bibr" rid="article-151525.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Trauma</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Open globe injury</p>
          </list-item>
          <list-item>
            <p>Closed globe injury</p>
          </list-item>
          <list-item>
            <p>Chemical injury</p>
          </list-item>
          <list-item>
            <p>Thermal injury&#x000a0;<xref ref-type="bibr" rid="article-151525.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Surgical Intervention&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gunderson flap</p>
          </list-item>
          <list-item>
            <p>Cataract surgery&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Penetrating keratoplasty&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Glaucoma surgery</p>
          </list-item>
          <list-item>
            <p>Para plana vitrectomy</p>
          </list-item>
          <list-item>
            <p>Diode cyclophotocoagulation</p>
          </list-item>
          <list-item>
            <p>Scleral buckle</p>
          </list-item>
          <list-item>
            <p>Intravitreal injections</p>
          </list-item>
          <list-item>
            <p>Enucleation</p>
          </list-item>
          <list-item>
            <p>Evisceration</p>
          </list-item>
          <list-item>
            <p>Treatment of choroidal melanoma with proton bean</p>
          </list-item>
          <list-item>
            <p>Iridectomy</p>
          </list-item>
          <list-item>
            <p>Iridenclesis</p>
          </list-item>
          <list-item>
            <p>Iris&#x000a0;incarceration in wound</p>
          </list-item>
          <list-item>
            <p>Paracentesis</p>
          </list-item>
          <list-item>
            <p>Phakic intraocular lens implantation&#x000a0;<xref ref-type="bibr" rid="article-151525.r19">[19]</xref><xref ref-type="bibr" rid="article-151525.r20">[20]</xref><xref ref-type="bibr" rid="article-151525.r21">[21]</xref><xref ref-type="bibr" rid="article-151525.r22">[22]</xref><xref ref-type="bibr" rid="article-151525.r23">[23]</xref><xref ref-type="bibr" rid="article-151525.r24">[24]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Ocular Pathologies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fungal keratitis</p>
          </list-item>
          <list-item>
            <p>Bacterial keratitis</p>
          </list-item>
          <list-item>
            <p>Acanthamoeba keratitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151525.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>A commonly cited general incidence of sympathetic ophthalmia is around 0.03 per 100,000 persons per year.<xref ref-type="bibr" rid="article-151525.r11">[11]</xref> A retrospective analysis of sympathetic ophthalmia cases demonstrated around 62.7% of cases are secondary to accidental injury, and 34.5% are secondary to surgical trauma.<xref ref-type="bibr" rid="article-151525.r25">[25]</xref> The incidence of patients developing sympathetic ophthalmia after traumatic eye injury was 0.19%.&#x000a0;The incidence of patients developing disease following vitreoretinal surgery was significantly lower, around 0.038%.&#x000a0;Repeated inciting events, especially patients with repeated traumatic injuries, are at the greatest risk of developing sympathetic ophthalmia.</p>
        <p>The average age&#x000a0;of presentation for sympathetic ophthalmia&#x000a0;is usually between 40 and 45.<xref ref-type="bibr" rid="article-151525.r26">[26]</xref><xref ref-type="bibr" rid="article-151525.r27">[27]</xref><xref ref-type="bibr" rid="article-151525.r28">[28]</xref>&#x000a0;Several studies have also&#x000a0;suggested a gender preference, with&#x000a0;men having sympathetic ophthalmia at higher rates than women.<xref ref-type="bibr" rid="article-151525.r29">[29]</xref><xref ref-type="bibr" rid="article-151525.r30">[30]</xref>&#x000a0;The timeline for the onset of inflammation after trauma or surgery can vary from weeks to decades after the inciting event, with the most significant risk period being within&#x000a0;1 year. 50% of patients&#x000a0;have onset of symptoms within&#x000a0;3 months, and 90% of patients within&#x000a0;1 year.<xref ref-type="bibr" rid="article-151525.r31">[31]</xref> Notably, a reported case of sympathetic ophthalmia began 66 years after the inciting traumatic injury.<xref ref-type="bibr" rid="article-151525.r2">[2]</xref></p>
        <p>Gomi and colleagues have indicated that sympathetic ophthalmia accounts for approximately 0.3% of all uveitis presentations. Further research posits that the incidence could range between 0.2% and 1% following penetrating ocular injuries and around 0.01% after intraocular surgical procedures.&#x000a0;Liddy and Stuart observed that&#x000a0;sympathetic ophthalmia&#x000a0;manifested in 0.2% of non-surgically inflicted ocular injuries, distinguishing that 0.19% resulted from penetrating trauma and a mere 0.007% post intraocular surgery. Holland&#x02019;s findings denote that sympathetic ophthalmia occurs in 0.5% of ocular trauma cases. Gass and colleagues noted a prevalence of 0.01% after standard pars plana vitrectomy, which escalated to 0.06% when the vitrectomy was associated with penetrating trauma.<xref ref-type="bibr" rid="article-151525.r32">[32]</xref></p>
        <p>A&#x000a0;higher preference&#x000a0;exists for post-traumatic sympathetic ophthalmia in men, with incidence rates being 1.8-fold greater in comparison to women&#x02014;likely linked to greater exposure to occupational risks and a predominance of outdoor activities. Conversely, the incidence rate of post-surgical sympathetic ophthalmia is analogous between the sexes, with recent trends indicating a rise in cases. Castiblanco and team found that post-surgical events contribute to 44% of sympathetic ophthalmia cases, with 21% arising after pars plana vitrectomy. A recurrent theme in these occurrences is the presence of a penetrating injury that leads to complex wound-healing challenges, often compounded by the entrapment of ocular structures such as the iris, ciliary body, or choroid.<xref ref-type="bibr" rid="article-151525.r33">[33]</xref></p>
      </sec>
      <sec id="article-151525.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>The Mechanism of Pathology</bold>
</p>
        <p>The precise pathophysiology of sympathetic ophthalmia is not clearly understood; however, most evidence points to an autoimmune inflammatory process secondary to ocular injury following trauma or surgery.<xref ref-type="bibr" rid="article-151525.r34">[34]</xref> The eye is&#x000a0;an immune-privileged space in the body where systemic immune responses to antigens are markedly reduced. This is achieved by the absence of intraocular lymphatics and tight junctions in the retinal pigment epithelium, creating&#x000a0;the blood-retina barrier.<xref ref-type="bibr" rid="article-151525.r35">[35]</xref>&#x000a0;Disruption of this system in penetrating injuries results in exposure of previously sequestered ocular antigens to local conjunctival lymphatics, activating cell-mediated immunity and a type IV delayed hypersensitivity reaction.<xref ref-type="bibr" rid="article-151525.r36">[36]</xref></p>
        <p>Though no singular culprit has been identified as the antigen responsible for sympathetic ophthalmia, several ocular antigens have been implicated, including arrestin (S-antigen), recoverin, rhodopsin, melanocyte-associated tyrosinase, interphotoreceptor retinoid-binding protein, and retinal pigment epithelium associated antigens. These have been studied in animal models and shown to produce autoimmune uveitic reactions that mimic sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r37">[37]</xref><xref ref-type="bibr" rid="article-151525.r38">[38]</xref><xref ref-type="bibr" rid="article-151525.r39">[39]</xref><xref ref-type="bibr" rid="article-151525.r40">[40]</xref>&#x000a0;Genetic predisposition&#x000a0;to sympathetic ophthalmia is another emerging area of research, enabling the identification of at-risk patient populations. Human leukocyte antigen (HLA)-DR4, HLA-A11, and HLA-B40 are associated with sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r41">[41]</xref></p>
        <p>More recent studies have&#x000a0;demonstrated that the expression of HLA-DRB1*04 and HLA-DQA1*03 is significantly associated with sympathetic ophthalmia across white and Japanese patients.<xref ref-type="bibr" rid="article-151525.r42">[42]</xref><xref ref-type="bibr" rid="article-151525.r43">[43]</xref>&#x000a0;Accidental penetrating injuries and iatrogenic surgical trauma are the primary precursors in 60% to 70% and 30% of sympathetic ophthalmia cases, respectively. Historically considered exacerbated by infectious agents, current understanding confirms that&#x000a0;the condition predominantly arises without intraocular infection. Research conducted by Marak and subsequent studies by Wong et al have elucidated that patients exhibit lymphocytes that react to specific uveal-retinal antigens. These findings underscore the pivotal role of genetic predispositions in the etiopathogenesis of sympathetic ophthalmia. Notably, associations have been identified with specific HLA haplotypes, namely HLA-A11, HLA-B40, HLA-DR4/DRw53, and HLA-DR4/DQw3. Moreover, a notable correlation has been established between HLA-DRB14 and HLA-DQB104 alleles and the susceptibility to sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r44">[44]</xref></p>
        <p>The pathophysiological mechanism underlying&#x000a0;sympathetic ophthalmia&#x000a0;is hypothesized to initiate with an iatrogenic or traumatic event that triggers the afferent arm of an autoimmune response, possibly due to the unveiling of hidden ocular antigens to the immune system or a disruption in immune tolerance to these antigens.<xref ref-type="bibr" rid="article-151525.r45">[45]</xref> Despite the absence of a traditional lymphatic system in the eye, antigen-presenting cells, predominantly macrophages or dendritic cells, process the ocular antigen and present&#x000a0;the peptides to autoreactive CD4+ T cells, specifically Th1 cells via HLA class II molecules within the lymph nodes or spleen. The interaction of the antigen peptide with the T cell receptor results in Th1 cell activation and proliferation. These autoreactive cells traverse to the ocular tissues, where a confluence of altered endothelial integrity, a shift in cytokine profiles, and the activation of several effector pathways culminate in damage to the sympathizing eye.<xref ref-type="bibr" rid="article-151525.r46">[46]</xref></p>
        <p>
<bold>Immunological Cascade</bold>
</p>
        <p>A widespread granulomatous inflammation within the uveal tract defines the immunopathological profile of sympathetic ophthalmia. This reaction comprises an aggregation of lymphocytes, plasma cells, and clusters of epithelioid histiocytes. Notably, pigmentation is often identified within these epithelioid cells and giant cells. A distinctive characteristic is that the inflammation does not extend to involve the choriocapillaris or the retina in histopathological specimens.<xref ref-type="bibr" rid="article-151525.r4">[4]</xref>&#x000a0;The choroid remains the primary focus of inflammatory activity, while retinal involvement is typically minimal. Clinically, Dalen&#x02013;Fuchs nodules present as yellow-white lesions within the peripheral retina, which can progress toward the optic disc and potentially affect the posterior pole. The frequency of&#x000a0;Dalen-Fuchs nodules in cases of sympathetic ophthalmia ranges from 25% to 35%. However, this incidence rises to 41.5% when a single peripheral nodule is considered indicative of the disease.<xref ref-type="bibr" rid="article-151525.r3">[3]</xref> These nodules exhibit various morphologies: some display focal hyperplasia of the retinal pigment epithelium, while others show intact retinal pigment epithelium overlying lymphocytes and epithelioid cells. In more advanced stages,&#x000a0;the degeneration and disorganization of the nodules can occur, leading to the subretinal discharge of the nodular contents.<xref ref-type="bibr" rid="article-151525.r47">[47]</xref></p>
        <p>Initially, the physical mass of nodules results in an apparent elevation of the overlying retinal structures, which, over time, gives way to atrophic changes. These nodules consist of nodular accumulations of pigmented epithelioid cells between the retinal pigment epithelium and Bruch membrane. Under microscopic examination, these cells reveal a distinctive ultrastructure featuring prominent organelles consistent with an active metabolic state. Autofluorescence studies reveal these cells as innumerable yellowish-orange specks corresponding to lipofuscin, reinforcing the theory that transformed cells constitute the primary cellular component of&#x000a0;Dalen-Fuchs nodules.<xref ref-type="bibr" rid="article-151525.r48">[48]</xref>&#x000a0;When&#x000a0;the retina typically remains unscathed, mononuclear cellular aggregates around blood vessels and over Dalen-Fuchs nodules have been observed in enucleated specimens. The sclera may also be implicated along emissary veins, and inflammatory exudates have been noted to extend to the optic nerve and meninges. Atypical histopathological features have been documented, such as phaco anaphylactic reactions to the disrupted lens material characterized by zonal granulomatous inflammation.<xref ref-type="bibr" rid="article-151525.r49">[49]</xref></p>
        <p>Immunohistochemical analyses have identified a predominance of T lymphocyte infiltration within the uveal tract, with B lymphocyte presence in more protracted cases or those managed with corticosteroids. The early stages of the disease are characterized by a Th1 response, marked by an abundance of CD4+ T cells and the secretion of proinflammatory cytokines. In contrast, CD8+ T cells are more common in chronic presentations of sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r50">[50]</xref> Emerging research implicates TNF-&#x003b1;-induced oxidative stress within the outer retina as a potential early event precipitating photoreceptor apoptosis and subsequent vision impairment in sympathetic ophthalmia. Conversely, protective molecular markers, such as &#x003b1;-A-crystallin, have been detected in the outer retinal layers. The increased expression of Fas and FasL in afflicted eyes hints at apoptosis playing a regulatory role in mitigating ocular inflammation.<xref ref-type="bibr" rid="article-151525.r51">[51]</xref>&#x000a0;Interleukin-23 or interleukin-17 signaling has been implicated in autoinflammatory and autoimmune uveitis pathogenesis akin to sympathetic ophthalmia, influencing cell function and exacerbating intraocular inflammation. Targeting this pathway may represent a novel therapeutic approach. Additionally, altered expression of specific microRNAs has been associated with increased proinflammatory cytokine activity, particularly TNF-&#x003b1;, and NF-&#x003ba;B, underscoring their importance in the pathogenesis.<xref ref-type="bibr" rid="article-151525.r52">[52]</xref></p>
      </sec>
      <sec id="article-151525.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histopathology of sympathetic ophthalmia classically shows widespread bilateral uveal inflammation characterized by lymphocytes surrounding non-necrotizing granulomas composed of multinucleated giant cells and macrophages.<xref ref-type="bibr" rid="article-151525.r53">[53]</xref>&#x000a0;Notably, similar changes&#x000a0;are found&#x000a0;in the inciting and the sympathizing eye. Immunohistochemical studies demonstrate lymphocytic granulomatous uveal inflammation&#x000a0;where CD4+ T helper cells predominate during the early stages of the disease, followed by CD8+ T suppressor cells during later stages. More recent studies also unveiled B cells as potential contributors to the inflammatory process toward end-stage disease.<xref ref-type="bibr" rid="article-151525.r34">[34]</xref><xref ref-type="bibr" rid="article-151525.r54">[54]</xref>&#x000a0; TNF-&#x003b1;, an inflammatory cytokine, may mediate oxidative stress in the outer retina during sympathetic ophthalmia, resulting in photoreceptor apoptosis and vision loss.<xref ref-type="bibr" rid="article-151525.r55">[55]</xref>&#x000a0;Interleukin-23 and interleukin-17&#x000a0;may also target&#x000a0;retinal pigment epithelial cells in this disease. Classically, inflammation from sympathetic ophthalmia spares the choriocapillaris, though some recent studies have&#x000a0;documented cases where the choriocapillaris can be involved.<xref ref-type="bibr" rid="article-151525.r56">[56]</xref><xref ref-type="bibr" rid="article-151525.r57">[57]</xref>&#x000a0;</p>
        <p>Dalen-Fuchs nodules are lesions of the retinal pigment epithelium characteristically associated with sympathetic ophthalmia. Still, they are only seen in 25% to 35% of cases and are not pathognomonic to the disease.<xref ref-type="bibr" rid="article-151525.r58">[58]</xref>&#x000a0;Dalen&#x02013;Fuchs nodules are present in an estimated 30% of patients. These microscopic structures comprise lymphocytes, histiocytes, and altered retinal pigment epithelial cells beneath the Bruch membrane.&#x000a0;Morphological diversity in these nodules&#x000a0;occurs. Descriptions outline&#x000a0;3&#x000a0;distinct types of lesions: the first involves localized proliferation and clustering of retinal pigment epithelial&#x000a0;cells, the second is the traditional Dalen&#x02013;Fuchs nodule, where a continuous layer caps epithelioid cells and lymphocytes, and the third&#x000a0;is characterized&#x000a0;by degenerative changes, leading to disorganized nodules and potential dispersion into the subretinal region.<xref ref-type="bibr" rid="article-151525.r3">[3]</xref>&#x000a0;Three different morphologies of these lesions follow:</p>
        <list list-type="bullet">
          <list-item>
            <p>Focal&#x000a0;retinal pigment epithelial&#x000a0;hyperplasia and aggregation</p>
          </list-item>
          <list-item>
            <p>Classic Dalen-Fuchs nodules, described as lymphocytes and epithelioid cells that exist between retinal pigment epithelial and Bruch membrane</p>
          </list-item>
          <list-item>
            <p>Nodules with disruption of the overlying retinal pigment epithelial resulting in potential eruption into the subretinal space&#x000a0;<xref ref-type="bibr" rid="article-151525.r59">[59]</xref></p>
          </list-item>
        </list>
        <p>No&#x000a0;known correlation exists between the extent of histopathological findings and the final visual outcome&#x000a0;in sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r56">[56]</xref>&#x000a0;Sympathetic ophthalmia is a comprehensive inflammatory eye disease that manifests as panuveitis. Upon histological examination, the disease exhibits a pervasive thickening throughout the uveal tract, including the choroid, ciliary body, and iris. Notably, the inflammatory alterations are comparable in both the triggering and the affected eye. Though the proportions vary, the inflammatory response predominantly comprises lymphocytes, epithelioid cells, and multinucleated giant cells. Traditionally,&#x000a0;the condition is understood to spare the choriocapillaris; however, research by Rathinam&#x000a0;et al&#x000a0;uncovered instances of lymphocytic infiltration within the choriocapillaris in select regions, alongside focal necrosis in cases where&#x000a0;sympathetic ophthalmia&#x000a0;is concurrent with endophthalmitis.<xref ref-type="bibr" rid="article-151525.r60">[60]</xref></p>
        <p>Immunopathologically, the condition is marked by an initial surge of CD4+ helper or inducer T cells, with a subsequent rise in CD8+ suppressor or cytotoxic T cells, illustrating an active and changing T cell-mediated immune response during&#x000a0;the progression. Additionally, B cells within the uveal infiltrate have&#x000a0;been observed, contrasting with the previously believed T cell dominance and suggesting the potential role of B cell-mediated activation of autoreactive T cells as the disease progresses.&#x000a0;Evidence suggests&#x000a0;genetic factors may contribute to the susceptibility to sympathetic ophthalmia, particularly alleles in the human leukocyte antigen system, such as HLA-A11, Cw, DRB104, DQB104, DR4, as well as the related DQw3 and DRw53.<xref ref-type="bibr" rid="article-151525.r61">[61]</xref></p>
      </sec>
      <sec id="article-151525.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The timeline for the onset of sympathetic ophthalmia can range from days to years after the initial injury to the inciting eye; however, 90% of cases occur within&#x000a0;1&#x000a0;year.<xref ref-type="bibr" rid="article-151525.r31">[31]</xref>&#x000a0;Patients with sympathetic ophthalmia may have significant variability&#x000a0;in their initial presentation. Unfortunately, patients may experience recurrent episodes despite resolution after the initial episode. Upon seeing patients with bilateral uveitis, an accurate history&#x000a0;focuses on whether the patient has had a history of traumatic ocular injury or prior eye surgeries. Early-stage sympathetic ophthalmia may present with isolated mild anterior segment inflammation or isolated posterior segment inflammation. Detection during this early stage may lead to a better visual prognosis with&#x000a0;prompt treatment.<xref ref-type="bibr" rid="article-151525.r30">[30]</xref></p>
        <p>Symptoms may range from mild visual disturbances to significant vision loss. Other symptoms include pain, photophobia, epiphora, floaters, and redness.<xref ref-type="bibr" rid="article-151525.r26">[26]</xref><xref ref-type="bibr" rid="article-151525.r62">[62]</xref>&#x000a0;Due to inflammation of the ciliary body affecting accommodation, near vision may be affected during the early stages of sympathetic ophthalmia. Most patients have asymmetric bilateral uveitis, displaying more significant inflammation in the inciting eye.&#x000a0;Anterior segment findings may range from mild bilateral anterior segment inflammation to bilateral granulomatous inflammation with mutton-fat corneal precipitates. Posterior iris synechiae and peripheral anterior synechiae may be present. Iris thickening with or without iris nodules&#x000a0;is seen. Intraocular pressure&#x000a0;is low in the setting of ciliary body shutdown or high secondary to trabeculitis or obstruction of the trabecular meshwork.</p>
        <p>Examination of the posterior segment in cases of sympathetic ophthalmia commonly reveals a spectrum of inflammatory manifestations, including vitreous haze and opacities, inflammation of the optic nerve head, inflammation of the retinal blood vessels, serous retinal separation, and inflammation of the vascular layer beneath the retina. The initial indicators often involve subtle inflammation in the front of the eye, minimal cells behind the lens, and optic disc redness. The severity of the inflammatory response can range from minor, with several small, isolated serous detachments near the optic nerve and macula, to extensive serous retinal separation. These presentations may include discreet yellowish-white spots at the choroidal level in the early stages, commonly identified as Dalen&#x02013;Fuchs nodules.&#x000a0;They are typically observed around the eye&#x02019;s equator and peripheral regions.<xref ref-type="bibr" rid="article-151525.r63">[63]</xref></p>
        <p>Over time, these nodules are prone to degenerative changes, leading to thinning and atrophy. The pattern and magnitude of the fluid accumulation beneath the retina&#x000a0;are&#x000a0;quite&#x000a0;variable, sometimes presenting as localized detachments in the region adjacent to the optic disc across the central retinal area or as a more extensive detachment scenario. Though indicative of the underlying inflammatory process, these nodules are often a marker of disease progression and the body&#x02019;s response to the condition. Posterior segment exam findings may include mild to severe vitritis, Dalen-Fuch nodules (yellow-white lesions of the retinal pigment epithelium), choroiditis, papillitis, and retinal vasculitis. Exudative retinal detachment may vary from small pockets of peripapillary exudative detachments to more extensive serous retinal detachments.<xref ref-type="bibr" rid="article-151525.r3">[3]</xref><xref ref-type="bibr" rid="article-151525.r26">[26]</xref>&#x000a0;</p>
        <p>Chronic sympathetic ophthalmia may also cause subretinal fibrosis and choroidal neovascularization.<xref ref-type="bibr" rid="article-151525.r4">[4]</xref>&#x000a0;A late-stage finding of sympathetic ophthalmia is the&#x000a0;&#x0201c;sunset glow fundus,&#x0201d; where the retina has a red-orange appearance due to depigmentation of the inflamed choroid and retinal pigment epithelium.<xref ref-type="bibr" rid="article-151525.r64">[64]</xref>&#x000a0;The&#x000a0;&#x0201c;sunset glow&#x0201d; fundus, a hallmark characteristic often observed in the advanced stages of sympathetic ophthalmia, emerges due to pigmentary depletion within the choroidal layer and alterations in the retinal pigment epithelium. Recurrent inflammation in the front part of the eye, accompanied by this&#x000a0;&#x0201c;sunset glow&#x0201d; appearance, is a notable clinical manifestation of sympathetic ophthalmia. The range of post-inflammatory sequelae varies widely and&#x000a0;is influenced&#x000a0;by the intensity of the inflammation and the timeliness and effectiveness of the treatment. Complications such as secondary glaucoma and cataract formation are frequently encountered, either as direct consequences of the disease or as adverse effects of corticosteroid therapy. Additionally, atrophy of the retina and optic nerve can develop as a sequel to persistent retinal separation, subretinal scarring, and attendant atrophic changes in the choroid. Although less common, the development of choroidal neovascularization and phthisis&#x000a0;bulbi&#x000a0;are serious complications that typically indicate a history of delayed diagnosis or suboptimal management.<xref ref-type="bibr" rid="article-151525.r65">[65]</xref></p>
      </sec>
      <sec id="article-151525.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Essential for diagnosing sympathetic ophthalmia&#x000a0;are the characteristic findings of bilateral uveitis following an event of trauma or surgical intervention to&#x000a0;1 eye. This condition presents with inflammation across multiple eye segments involving the anterior chamber, vitreous body, and choroid. While the diagnosis primarily rests on clinical grounds, a suite of imaging techniques is pivotal for confirming and tracking treatment efficacy and disease course. These supplemental diagnostic measures are instrumental for clinicians in comprehensively managing sympathetic ophthalmia. The SUN working group criteria for sympathetic ophthalmia diagnosis is a patient with a history of unilateral ocular trauma or surgery with ocular inflammation in both eyes and either anterior uveitis with vitreous inflammation or panuveitis with choroidal involvement.<xref ref-type="bibr" rid="article-151525.r1">[1]</xref>&#x000a0;Though sympathetic ophthalmia&#x000a0;remains a clinical diagnosis, multiple imaging modalities&#x000a0;can&#x000a0;assist ophthalmologists in confirming the diagnosis, tracking disease progression, and monitoring response to treatment.</p>
        <p>
<bold>B-Scan Ultrasonography</bold>
</p>
        <p>B-scan ultrasonography may reveal diffuse choroidal thickening and serous retinal detachments. B-scan is particularly valuable in the case of dense vitritis, posterior synechiae, corneal opacity, or any other pathology&#x000a0;that prevents&#x000a0;a clear view&#x000a0;of the retina.<xref ref-type="bibr" rid="article-151525.r4">[4]</xref><xref ref-type="bibr" rid="article-151525.r66">[66]</xref>&#x000a0;Enhanced-depth imaging optical coherence tomography (EDI-OCT) is the preferred method for assessing choroidal thickness. Research indicates that individuals with sympathetic ophthalmia often exhibit widespread choroidal swelling and a mild serous retina detachment, particularly in the macular region.</p>
        <p>
<bold>Fundus Autofluorescence</bold>
</p>
        <p>The imaging&#x000a0;detects lipofuscin in the retinal pigment epithelium, enabling visualization of dysfunction and death. This simple, noninvasive test is&#x000a0;useful&#x000a0;in assessing sympathetic ophthalmia,&#x000a0;showing the extent of damage caused by inflammation and helping identify potential sequelae like choroidal neovascularization. In acute disease, a petaloid pattern of hyper-autofluorescence centered on the optic nerve may be present in areas of serous retinal detachments.<xref ref-type="bibr" rid="article-151525.r67">[67]</xref>&#x000a0;With the resolution of the subretinal fluid, fundus autofluorescence (FAF)&#x000a0;may display leopard spots with mixed areas of hyper- and hypo-autofluorescence.<xref ref-type="bibr" rid="article-151525.r68">[68]</xref>&#x000a0;</p>
        <p>Fundus autofluorescence in chronic sympathetic ophthalmia&#x000a0;has a varied presentation depending on the sequelae of the disease, as previously described. Decreased autofluorescence may be detected secondary to outer retinal damage,&#x000a0;retinal pigment epithelial loss, nummular scars, and peripapillary atrophy. Increased autofluorescence may&#x000a0;be seen&#x000a0;in&#x000a0;cystic macular edema, subretinal fibrosis, and proliferation.<xref ref-type="bibr" rid="article-151525.r69">[69]</xref>&#x000a0;During active phases of the disease, enhanced autofluorescence imaging reveals intensified signals that align with areas where the neurosensory retina has detached. As the disease resolves, leading to alterations in the retinal pigment epithelium, the autofluorescence patterns evolve, displaying a speckled increase in autofluorescence that resembles leopard spotting. Autofluorescence imaging is&#x000a0;useful&#x000a0;to assess the condition, where increased autofluorescence signifies a metabolically active epithelium, and decreased signals indicate loss. Nevertheless, since sympathetic ophthalmia primarily affects the choroidal stroma, imaging does not&#x000a0;facilitate&#x000a0;diagnosing or managing the condition.<xref ref-type="bibr" rid="article-151525.r70">[70]</xref></p>
        <p>
<bold>Optical Coherence Tomography</bold>
</p>
        <p>The introduction of enhanced depth imaging OCT (EDI-OCT) and swept-source OCT technologies has revolutionized the visualization of retinal and choroidal structures, producing high-definition images spectral-domain optical coherence tomography (SD-OCT) with or without enhanced depth imaging (EDI-OCT) and swept-source OCT (SS-OCT) are noninvasive imaging modalities that allow for high-resolution examination of the retina and choroid.<xref ref-type="bibr" rid="article-151525.r71">[71]</xref>&#x000a0;Sympathetic ophthalmia may initially present with serous retinal detachments seen on swept-source OCT.&#x000a0;The detachments&#x000a0;contain hyperreflective septa, representing bacillary layer detachment splitting the photoreceptor layer at the inner segment myoid. Of note is that this finding is also seen in Vogt-Kayanagi-Harada (VKH) disease and resolves rapidly with corticosteroid treatment.<xref ref-type="bibr" rid="article-151525.r72">[72]</xref>&#x000a0;Dalen-Fuchs nodules, classically seen in 25% to 35% of patients with sympathetic ophthalmia, initially appear as round hyperreflective areas in the outer retina with occasional serous detachments of the overlying neurosensory retina. These lesions&#x000a0;regress with therapy.<xref ref-type="bibr" rid="article-151525.r73">[73]</xref>&#x000a0;EDI-OCT and SS-OCT can also identify the presence of choroidal thickening, subretinal choroidal folds, and increased choroidal vascularity index. These findings typically resolve with treatment, though&#x000a0;useful&#x000a0;in monitoring treatment response.<xref ref-type="bibr" rid="article-151525.r74">[74]</xref><xref ref-type="bibr" rid="article-151525.r75">[75]</xref>&#x000a0;</p>
        <p>Research conducted by Gupta and colleagues noted the repair of these OCT-detected abnormalities, including the continuity of the retinal pigment epithelium&#x02013;Bruch membrane complex and inner segment and outer segment of photoreceptor cells junction, following timely treatment in the acute phase of the disease. Furthermore, acute-phase alterations in the choroid are not limited to the outer retina but include extensive choroidal thickening, observable folds, and a loss of&#x000a0;normal&#x000a0;choroidal structure. Such choroidal thickening&#x000a0;is a significant OCT-based biomarker for tracking disease progression. The choroidal vascularity index (CVI), a novel OCT biomarker, has been introduced to monitor disease activity in cases of sympathetic ophthalmia. Notably, the CVI&#x000a0;is considered&#x000a0;a reliable metric, remaining constant and less susceptible to alteration by physiological variables.</p>
        <p>
<bold>Optical Coherence Tomography Angiography</bold>
</p>
        <p>This noninvasive imaging modality&#x000a0;is&#x000a0;designed&#x000a0;to examine the chorioretinal vasculature without intravenous dye. Optical coherence tomography angiography (OCTA) may demonstrate ischemia&#x000a0;and&#x000a0;reduced capillary density.<xref ref-type="bibr" rid="article-151525.r76">[76]</xref>&#x000a0;OCTA can also monitor&#x000a0;ischemic areas as patients respond to therapy.<xref ref-type="bibr" rid="article-151525.r4">[4]</xref><xref ref-type="bibr" rid="article-151525.r77">[77]</xref>&#x000a0;OCTA is also sensitive in detecting and differentiating choroidal neovascularization from inflammatory lesions&#x000a0;to tailor the patient&#x02019;s treatment plan.<xref ref-type="bibr" rid="article-151525.r78">[78]</xref>&#x000a0;OCTA&#x000a0;has been pivotal in identifying small regions of compromised choriocapillaris perfusion, suggesting areas of ischemia within the choriocapillaris. These areas appear as flow voids on OCTA images, which typically diminish and resolve with appropriate treatment. OCTA has also enhanced the visualization of choroidal neovascular membranes, providing&#x000a0;clearer&#x000a0;images than other imaging modalities.<xref ref-type="bibr" rid="article-151525.r79">[79]</xref>&#x000a0;In contrast to fluorescein angiography and indocyanine green angiography (ICGA), which yield 2-dimensional images, OCTA generates 3-dimensional visualizations based on volumetric data; this&#x000a0;provides&#x000a0;a more detailed analysis of the choriocapillaris and ischemic conditions, which often present as flow voids on OCTA and are analogous to the hypocyanescent lesions seen on indocyanine green angiography in inflammatory choroidal diseases such as Vogt-Koyanagi-Harada and sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r80">[80]</xref>&#x000a0;</p>
        <p>Despite&#x000a0;the advantages as a noninvasive imaging technique, especially for conditions affecting the choriocapillaris, OCTA has limitations in adequately capturing medium and&#x000a0;large&#x000a0;choroidal vessel details. Additionally, signal loss and artifacts can complicate the interpretation of flow voids, necessitating careful differentiation and occasionally leaving the utility of OCTA somewhat ambiguous. The primary basis for diagnosis&#x000a0;remains the patient&#x02019;s history of ocular trauma and the presentation of clinical features. Multimodal imaging continues to be essential for tracking the disease&#x02019;s progression, identifying recurrences, and evaluating therapeutic responses. Advanced OCT technologies have facilitated the noninvasive assessment of&#x000a0;retinochoroidal&#x000a0;microstructural and microvascular alterations in diseases like&#x000a0;sympathetic ophthalmia&#x000a0;and Vogt-Koyanagi-Harada. OCTA, in particular, is an increasingly favored instrument in diagnosing and managing choroidal disorders, attesting to its utility in ophthalmic practice.<xref ref-type="bibr" rid="article-151525.r81">[81]</xref></p>
        <p>
<bold>Fluorescein Angiography</bold>
</p>
        <p>This excellent noninvasive imaging modality provides&#x000a0;useful&#x000a0;information for the diagnosis and treatment monitoring of patients with sympathetic ophthalmia. In the acute phase of sympathetic ophthalmia,&#x000a0;2&#x000a0;patterns&#x000a0;are seen. The first is nearly identical to the pattern seen in Vogt-Koyanagi-Harada with initial diffuse pinpoint hyperfluorescent spots with late leakage with or without hyperfluorescence of the disc. Another less common variant is initial multiple hypofluorescent spots with late-phase pooling.&#x000a0;These spots may coalesce under serous retinal detachments in severe disease.<xref ref-type="bibr" rid="article-151525.r82">[82]</xref>&#x000a0;The second acute phase pattern&#x000a0;resembles&#x000a0;acute posterior multifocal placoid pigment epitheliopathy (APMPPE), demonstrating initial&#x000a0;hypofluorescent&#x000a0;foci that&#x000a0;are hyperfluorescent in the late phase with staining of the lesions. Unlike APMPPE, the lesions in sympathetic ophthalmia are elevated and mottled in appearance.<xref ref-type="bibr" rid="article-151525.r83">[83]</xref>&#x000a0;The initial&#x000a0;hypofluorescence&#x000a0;may be secondary to obscuration from Dalen-Fuchs nodules or choroidal inflammation leading to focal obliteration of the choriocapillaris. Chronic&#x000a0;sympathetic ophthalmia findings are&#x000a0;more variable, depending on the inflammatory sequelae of the disease.&#x000a0;Nummular scars&#x000a0;occur&#x000a0;from focal damage to the&#x000a0;retinal pigment epithelium and inner choroid and present as window defects.<xref ref-type="bibr" rid="article-151525.r30">[30]</xref>&#x000a0;Subretinal fibrosis may present with hyperfluorescent staining due to proliferated metaplastic retinal pigment epithelium.<xref ref-type="bibr" rid="article-151525.r4">[4]</xref><xref ref-type="bibr" rid="article-151525.r84">[84]</xref>&#x000a0;The presence of choroidal neovascularization may reveal leakage in the macula.</p>
        <p>
<bold>Indocyanine Green Angiography&#x000a0;</bold>
</p>
        <p>Indocyanine green angiography (ICGA) is instrumental in examining the choroidal vasculature, significantly enhancing our understanding of the pathogenesis of diseases like sympathetic ophthalmia, which primarily affects the choroid. ICGA&#x000a0;is used&#x000a0;as an adjunct to fluorescein angiography, given&#x000a0;the superior ability to assess the choroid and choroidal infiltrates. A common finding in sympathetic ophthalmia on ICGA is multiple hypocyanescent spots corresponding to the hyperfluorescent spots. Histopathological studies of these lesions have confirmed&#x000a0;the&#x000a0;spots are caused by cellular infiltrates of the choroid or due to blockage by overlying fluid.<xref ref-type="bibr" rid="article-151525.r85">[85]</xref>&#x000a0;These hypocyanescent spots are similar in all phases of&#x000a0;sympathetic ophthalmia and tend to improve&#x000a0;with adequate treatment.<xref ref-type="bibr" rid="article-151525.r68">[68]</xref><xref ref-type="bibr" rid="article-151525.r86">[86]</xref>&#x000a0;The hypocyanescent spots may return in late-phase sympathetic ophthalmia, possibly due to choroidal atrophy.<xref ref-type="bibr" rid="article-151525.r87">[87]</xref>&#x000a0;Bernasconi and colleagues have further explored these observations, noting that&#x000a0;the presentation may indicate scarred lesions. In contrast,&#x000a0;the diminishment signals active inflammatory lesions. Importantly, these hypocyanescent lesions typically resolve with corticosteroid treatment, a change that correlates closely with clinical improvement in patients. This dynamic reflects the critical role of ICGA in guiding the diagnosis and monitoring the treatment response, providing a clearer picture of the choroidal involvement and the effectiveness of therapeutic interventions.</p>
      </sec>
      <sec id="article-151525.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Surgical</bold>
</p>
        <p>Historically, removal of the injured eye within 14 days of ocular trauma protects the contralateral eye from the onset of sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r58">[58]</xref>&#x000a0;When sympathetic ophthalmia occurs, enucleation no longer benefits the sympathizing eye.<xref ref-type="bibr" rid="article-151525.r29">[29]</xref>&#x000a0;However,&#x000a0;the practice of prophylactic enucleation lacks supporting scientific evidence and is based primarily on observation and clinical speculation.<xref ref-type="bibr" rid="article-151525.r88">[88]</xref>&#x000a0;Sympathetic ophthalmia&#x000a0;occurs in the sympathizing eye despite removing the traumatic globe.<xref ref-type="bibr" rid="article-151525.r89">[89]</xref>&#x000a0;Removing the&#x000a0;inciting eye&#x000a0;does not improve the sympathetic eye&#x02019;s visual acuity. In many patients, the inciting eye may&#x000a0;have better overall vision.<xref ref-type="bibr" rid="article-151525.r90">[90]</xref>&#x000a0;Importantly, in&#x000a0;most cases of ocular injury where the traumatic globe&#x000a0;was not removed, patients&#x000a0;do not develop sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r91">[91]</xref>&#x000a0;The decision of when to remove and when to save a severely traumatized eye is difficult. In a study of 660&#x000a0;traumatic globe injuries, over 98% of injuries&#x000a0;were successfully repaired&#x000a0;surgically, and only 13% resulted in&#x000a0;no light perception vision. Indication for primary removal of the globe only occurred in 1.7% due to the inability to repair the globe.<xref ref-type="bibr" rid="article-151525.r92">[92]</xref>&#x000a0;Additionally, patients with&#x000a0;no light perception vision after ocular trauma regain&#x000a0;some&#x000a0;vision in 16% of&#x000a0;cases.<xref ref-type="bibr" rid="article-151525.r93">[93]</xref>&#x000a0;Furthermore, the negative psychological impact of losing an eye cannot be understated and should&#x000a0;be&#x000a0;considered&#x000a0;before enucleation or evisceration. Patients&#x000a0;often experience body dysmorphia, depression, and increased anxiety from losing&#x000a0;an eye.<xref ref-type="bibr" rid="article-151525.r94">[94]</xref>&#x000a0;Cosmetic benefits include saving the&#x000a0;phthisical eye since the eye often retains&#x000a0;full&#x000a0;movement, and the irregular anterior surface better supports an overlying ocular prosthesis.<xref ref-type="bibr" rid="article-151525.r88">[88]</xref></p>
        <p>In cases where the ruptured globe is beyond repair, removal of the eye via evisceration or enucleation&#x000a0;is the only option. Significant debate exists as to which procedure is&#x000a0;more appropriate. Critics of evisceration argue that evisceration poses a potential risk for disseminating unsuspected uveal malignancy and a theoretical risk of causing sympathetic ophthalmia due to remnant uveal tissues.<xref ref-type="bibr" rid="article-151525.r95">[95]</xref>&#x000a0;However, a more recent large retrospective study of patients&#x000a0;showed no cases of sympathetic ophthalmia after evisceration.<xref ref-type="bibr" rid="article-151525.r62">[62]</xref>&#x000a0;Evisceration&#x000a0;is&#x000a0;favored since&#x000a0;this is&#x000a0;technically easier, and preserving the sclera can provide a barrier to prevent the orbital spread of infection. Evisceration&#x000a0;may also provide a cosmetic and functional advantage for the patient.</p>
        <p>
<bold>Medical</bold>
</p>
        <p>Patients with sympathetic ophthalmia who&#x000a0;undergo prompt treatment with high-dose steroids and immunomodulatory agents have a better chance for&#x000a0;positive visual outcomes.<xref ref-type="bibr" rid="article-151525.r96">[96]</xref>&#x000a0;The initial treatment for sympathetic ophthalmia typically involves administering high-dose systemic corticosteroids, with the specific regimen tailored according to the clinical presentation, disease severity, and initial visual acuity. In 1995, the National Eye Institute highlighted the efficacy of such high-dose systemic anti-inflammatory therapy, recommending corticosteroids at dosages ranging from 0.5 to 2 mg/kg/day of prednisolone to preserve vision. Upon diagnosis of sympathetic ophthalmia, initiating patients on high-dose intravenous corticosteroids at a dose of 1 to 2 mg/kg/day with adjunct topical cycloplegics and corticosteroids is recommended.<xref ref-type="bibr" rid="article-151525.r97">[97]</xref>&#x000a0;Improvements in retinal findings have been noted&#x000a0;soon after the initiation of corticosteroids.<xref ref-type="bibr" rid="article-151525.r98">[98]</xref>&#x000a0;In very severe cases, intravenous pulse methylprednisolone can be considered at a dose of 1 gram/day for&#x000a0;3&#x000a0;days.<xref ref-type="bibr" rid="article-151525.r7">[7]</xref>&#x000a0;Patients should remain on steroids for a minimum of 3 months with a very slow taper if improvement&#x000a0;is noted.</p>
        <p>Other immunosuppressive agents may be warranted if a patient experiences recurrence or worsened inflammation. Systemic corticosteroids may have significant complications, including uncontrolled diabetes, adrenal insufficiency, osteoporosis, and increased infection risk.&#x000a0;Intravitreal steroids can&#x000a0;be considered&#x000a0;to&#x000a0;avoid some of these systemic complications and enable a targeted high concentration of the drug at the site of the disease.&#x000a0;Studies have shown that intravitreal steroid therapy controls uveitic macular edema effectively.<xref ref-type="bibr" rid="article-151525.r99">[99]</xref><xref ref-type="bibr" rid="article-151525.r100">[100]</xref>&#x000a0;The results of another study&#x000a0;suggested the use of&#x000a0;intravitreal dexamethasone implants in place of systemic therapy; however, this is currently not the standard of care.<xref ref-type="bibr" rid="article-151525.r101">[101]</xref>&#x000a0;For severe cases characterized by iris nodules, pronounced granulomatous panuveitis, and serous retinal detachments, intravenous corticosteroid therapy is usually preferred. High-dose intravenous pulse therapy, often using methylprednisolone at&#x000a0;1&#x000a0;g/day for&#x000a0;3&#x000a0;days, quickly reduces significant pathological changes like vitritis, multifocal retinal detachments, and inflammation in the anterior chamber. Depending on the patient&#x02019;s response, this intravenous treatment might extend for&#x000a0;5 to&#x000a0;7 days.</p>
        <p>However,&#x000a0;the aggressive form of treatment&#x000a0;has potential risks, including rapid changes in blood pressure and blood glucose levels, along with serious side effects such as the possible reactivation of pulmonary tuberculosis. As such, these initial intensive treatments&#x000a0;should&#x000a0;be carefully managed, weighing the risks against the benefits. Following the control of the acute inflammatory phase, the regimen usually transitions to a lower dose of systemic corticosteroids, starting at 1 mg/kg/day of prednisolone, gradually tapered over&#x000a0;2 to&#x000a0;3 months. This duration allows for an adequate assessment of the treatment&#x02019;s effectiveness. Should further surgical interventions become necessary, increasing the corticosteroid dosage may be required to manage inflammation effectively.<xref ref-type="bibr" rid="article-151525.r102">[102]</xref>&#x000a0;Immunomodulators can be considered in patients with contraindications to steroid use, significant or intolerable side effects, or uncontrolled disease despite steroid therapy.&#x000a0;Up to 70% of patients with sympathetic ophthalmia need immunomodulatory therapy.<xref ref-type="bibr" rid="article-151525.r36">[36]</xref>&#x000a0;Immunosuppressive therapies are often prescribed for patients with sympathetic ophthalmia to minimize the dependence on prolonged systemic corticosteroid treatment. Typically, a regimen combining corticosteroids with immunosuppressive agents&#x000a0;is started&#x000a0;early in the treatment process, allowing sufficient time for the immunosuppressives to take effect. Additionally, alternative immunosuppressive drugs&#x000a0;are introduced&#x000a0;if a patient shows intolerance to a specific medication.<xref ref-type="bibr" rid="article-151525.r103">[103]</xref></p>
        <p>A variety of agents are available for the management of sympathetic ophthalmia. Commonly utilized medications include mycophenolate mofetil, azathioprine, cyclosporine, and cyclophosphamide. Cyclophosphamide&#x000a0;is generally reserved&#x000a0;for cases resistant to other treatments due to&#x000a0;the potential for severe systemic side effects. Most of these medications have significant systemic toxicities and require close monitoring; therefore, consultation with rheumatology or internal medicine specialists may&#x000a0;be recommended&#x000a0;for the co-management of these cases. Types of immunomodulators include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cyclosporine&#x000a0;is a calcineurin inhibitor that inhibits T-cell function. The recommended starting dose is 2.5&#x000a0;to 5 mg/kg/day. If improvement in a patient is noted for more than&#x000a0;3&#x000a0;months, a slow taper may&#x000a0;be initiated, decreasing by 0.5 mg/kg/day every 1 to 2 months. This medication can enable the control of severe inflammation in sympathetic ophthalmia.&#x000a0;Though well tolerated in children and adolescents, increased side effects&#x000a0;are noted&#x000a0;with advanced age.&#x000a0;Potential side effects include hepatotoxicity, nephrotoxicity, gingival hyperplasia, and hypertension.</p>
          </list-item>
          <list-item>
            <p>Azathioprine is an inhibitor of purine synthesis that affects B and T lymphocytes and effectively manages sympathetic ophthalmia. The recommended dose is 1 to 3 mg/kg/day. Given the risk of myelosuppression, close monitoring of complete blood count&#x000a0;is warranted&#x000a0;in these patients. Additional potential side effects include hepatotoxicity, pancreatitis, and increased risk for cancer.</p>
          </list-item>
          <list-item>
            <p>Mycophenolate mofetil is&#x000a0;an inhibitor of purine synthesis, better tolerated&#x000a0;than azathioprine, and has fewer side effects.&#x000a0;The medication is usually&#x000a0;dosed at 1 to 3 g/day and must&#x000a0;be taken&#x000a0;on an empty stomach.</p>
          </list-item>
          <list-item>
            <p>Alkylating agents like chlorambucil and cyclophosphamide control inflammation in sympathetic ophthalmia. However, these medications are associated with severe systemic side effects, including hemorrhagic cystitis, myelosuppression, secondary malignancies, and sterility. Therefore, patients should be monitored closely with internal medicine co-management.</p>
          </list-item>
          <list-item>
            <p>Anti-TNF-&#x003b1; biologic agents such as infliximab and adalimumab are gaining traction as potential first-line corticosteroid-sparing agents since they target the specific inflammatory cytokine involved in the pathogenesis of sympathetic ophthalmia. Adalimumab offers the convenience of a subcutaneous injection every&#x000a0;2&#x000a0;weeks, which can significantly improve a patient&#x02019;s quality of life. Importantly, before initiating therapy, patients should&#x000a0;undergo testing for tuberculosis, given the concern for disease reactivation.<xref ref-type="bibr" rid="article-151525.r4">[4]</xref><xref ref-type="bibr" rid="article-151525.r104">[104]</xref><xref ref-type="bibr" rid="article-151525.r105">[105]</xref><xref ref-type="bibr" rid="article-151525.r106">[106]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151525.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Vogt-Koyanagi-Harada syndrome is a well-delineated bilateral panuveitis that may mimic the presentation of sympathetic ophthalmia both on the clinical exam and in various imaging modalities. However, unlike sympathetic ophthalmia,&#x000a0;the syndrome is not associated with prior ocular trauma or surgery and tends to follow a more set evolutional disease progression. Classification criteria for the early stage of the syndrome include evidence of either exudative retinal detachment or panuveitis with at least&#x000a0;2&#x000a0;neurologic signs (headache, tinnitus, dysacusis, meningismus, or cerebrospinal fluid pleocytosis) and no history of prior ocular trauma or ocular surgery. Classification for late-stage includes evidence of early-stage&#x000a0;syndrome and either the presence of a sunset glow fundus or uveitis with cutaneous findings of vitiligo, poliosis, or alopecia.<xref ref-type="bibr" rid="article-151525.r107">[107]</xref>&#x000a0;Of note, systemic neurologic symptoms and cutaneous findings&#x000a0;are present in patients with sympathetic ophthalmia but with significantly lower frequency.<xref ref-type="bibr" rid="article-151525.r108">[108]</xref></p>
        <p>Vogt-Koyanagi-Harada&#x000a0;syndrome demonstrates a higher prevalence in certain groups, including the Asian, Hispanic, and Middle Eastern populations, and affects women with a higher frequency.<xref ref-type="bibr" rid="article-151525.r109">[109]</xref>&#x000a0;Sympathetic ophthalmia has no geographic predilection and occurs more in men than women. Patients with bilateral uveitis must also undergo a full systemic workup to rule out masquerading diseases such as lymphoma, tuberculosis, syphilis, and sarcoidosis.<xref ref-type="bibr" rid="article-151525.r7">[7]</xref><xref ref-type="bibr" rid="article-151525.r110">[110]</xref><xref ref-type="bibr" rid="article-151525.r111">[111]</xref>&#x000a0;Lymphoma workup should include a thorough neurologic evaluation and a vitreous sample should be obtained for cytologic analysis and flow cytometry. Tuberculosis, syphilis, and sarcoidosis usually present with systemic signs and symptoms, which should&#x000a0;be&#x000a0;elicited&#x000a0;when&#x000a0;obtaining&#x000a0;a history. Bacterial, viral, and fungal endophthalmitis may also be on the differential but typically do not involve both eyes. If the suspicion of endophthalmitis persists, a vitreous sample should&#x000a0;be obtained&#x000a0;for further testing. The list of differential diagnoses includes:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Vogt-Koyanagi-Harada disease:</bold>&#x000a0;This&#x000a0;is a panuveitis that includes serous retinal detachments and may present with systemic symptoms such as vitiligo, alopecia, and hearing loss.</p>
          </list-item>
          <list-item>
            <p><bold>Sarcoidosis:&#x000a0;</bold>A&#x000a0;systemic granulomatous disease can present with granulomatous uveitis mimicking&#x000a0;sympathetic ophthalmia and may&#x000a0;involve other organ systems.</p>
          </list-item>
          <list-item>
            <p><bold>Intraocular lymphoma:</bold>&#x000a0;This malignancy can cause uveitis and retinal detachment, requiring a biopsy for a definitive diagnosis.</p>
          </list-item>
          <list-item>
            <p><bold>Infectious uveitis</bold>: This includes tuberculosis, syphilis, and viral infections such as HSV and cytomegalovirus (CMV), which can cause panuveitis.</p>
          </list-item>
          <list-item>
            <p><bold>Beh&#x000e7;et disease:&#x000a0;</bold>A systemic vasculitis that can cause panuveitis, oral and genital ulcers,&#x000a0;and skin lesions.</p>
          </list-item>
          <list-item>
            <p><bold>Uveitis associated with juvenile idiopathic arthritis:</bold>&#x000a0;Juvenile idiopathic arthritis can be associated with chronic uveitis, especially in younger patients.</p>
          </list-item>
          <list-item>
            <p><bold>Posterior scleritis:&#x000a0;</bold>The condition&#x000a0;may cause painful inflammation&#x000a0;with similar fundus changes to sympathetic ophthalmia.</p>
          </list-item>
          <list-item>
            <p><bold>Ocular toxoplasmosis:</bold>&#x000a0;This&#x000a0;is infectious uveitis that can lead to retinal necrosis and choroiditis, sometimes similar to sympathetic ophthalmia.</p>
          </list-item>
          <list-item>
            <p><bold>Endophthalmitis:</bold>&#x000a0;Acute inflammation of the intraocular cavities, usually due to infection that can mimic the panuveitis seen in sympathetic ophthalmia.</p>
          </list-item>
          <list-item>
            <p><bold>Posterior uveitis of other causes:</bold>&#x000a0;Idiopathic or drug-induced causes.</p>
          </list-item>
          <list-item>
            <p><bold>Masquerade syndromes:&#x000a0;</bold>Conditions&#x000a0;that mimic intraocular inflammation but are not due to true uveitis, such as retinoblastoma in children or melanoma in adults.</p>
          </list-item>
          <list-item>
            <p><bold>Multifocal choroiditis with panuveitis</bold>&#x000a0;presents multiple choroidal lesions and inflammation resembling sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r112">[112]</xref><xref ref-type="bibr" rid="article-151525.r113">[113]</xref><xref ref-type="bibr" rid="article-151525.r114">[114]</xref><xref ref-type="bibr" rid="article-151525.r115">[115]</xref><xref ref-type="bibr" rid="article-151525.r116">[116]</xref><xref ref-type="bibr" rid="article-151525.r117">[117]</xref></p>
          </list-item>
        </list>
        <p>When assessing a patient, a comprehensive clinical examination, detailed patient history, and relevant ancillary tests are crucial for differentiating from these other conditions. An accurate diagnosis is vital for providing the correct treatment and improving the prognosis.</p>
      </sec>
      <sec id="article-151525.s11" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>Sympathetic ophthalmia does not have a universally accepted staging system like some other diseases, largely due to&#x000a0;its rarity. However, the clinical presentation of the disease can be described in terms of&#x000a0;the severity and the extent of ocular involvement. A potential approach to staging could consider the following factors:</p>
        <p>
<bold>Onset of Symptoms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acute</bold>: The sudden appearance of symptoms following trauma or surgery to the fellow eye, typically within days to months.</p>
          </list-item>
          <list-item>
            <p><bold>Delayed:</bold>&#x000a0;Symptoms manifesting months to years after the inciting event.<xref ref-type="bibr" rid="article-151525.r3">[3]</xref><xref ref-type="bibr" rid="article-151525.r118">[118]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mild:</bold>&#x000a0;Mild uveitis with slight discomfort, minimal visual impairment, and few inflammatory signs</p>
          </list-item>
          <list-item>
            <p><bold>Moderate:</bold>&#x000a0;More pronounced uveitis with moderate pain and visual impairment,&#x000a0;keratitic&#x000a0;precipitates, and vitreous haze</p>
          </list-item>
          <list-item>
            <p><bold>Severe:</bold>&#x000a0;Intense inflammation with significant pain, photophobia, severe vision loss, and the presence of exudative retinal detachments or choroidal neovascularization&#x000a0;<xref ref-type="bibr" rid="article-151525.r119">[119]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Anatomical Involvement</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Anterior uveitis:</bold>&#x000a0;Inflammation primarily in the iris and ciliary body</p>
          </list-item>
          <list-item>
            <p><bold>Intermediate uveitis</bold>: Inflammation centered in the vitreous</p>
          </list-item>
          <list-item>
            <p><bold>Posterior uveitis:</bold>&#x000a0;Inflammation affecting the retina and choroid</p>
          </list-item>
          <list-item>
            <p><bold>Panuveitis:</bold>&#x000a0;Involvement of all segments of the uvea&#x000a0;<xref ref-type="bibr" rid="article-151525.r120">[120]</xref></p>
          </list-item>
        </list>
        <p>
<bold>&#x000a0;The Extent&#x000a0;of Systemic Immune Response</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Localized:</bold>&#x000a0;Inflammation confined to the eyes with no systemic immune reaction</p>
          </list-item>
          <list-item>
            <p><bold>Systemic:</bold>&#x000a0;Evidence of a more generalized autoimmune response potentially affecting other organs&#x000a0;<xref ref-type="bibr" rid="article-151525.r121">[121]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage I:</bold>&#x000a0;No complications, inflammation controlled with medication</p>
          </list-item>
          <list-item>
            <p><bold>Stage II:</bold>&#x000a0;Development of complications such as cataracts or glaucoma, controllable with treatment</p>
          </list-item>
          <list-item>
            <p><bold>Stage III:</bold>&#x000a0;Complications such as chronic cystoid macular edema, optic atrophy, or subretinal neovascular membranes leading to irreversible vision loss&#x000a0;<xref ref-type="bibr" rid="article-151525.r122">[122]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Response to Treatment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Responsive:</bold>&#x000a0;The disease responds to initial therapy without&#x000a0;recurrence</p>
          </list-item>
          <list-item>
            <p><bold>Refractory:</bold>&#x000a0;Disease not adequately controlled with standard therapy, requiring more aggressive treatment or resulting in chronic condition&#x000a0;<xref ref-type="bibr" rid="article-151525.r123">[123]</xref></p>
          </list-item>
        </list>
        <p>This&#x000a0;staging is not officially recognized and is more for descriptive purposes, as clinicians often tailor treatment to the individual patient&#x02019;s condition rather than a specific stage. Due to the variability of the disease, a multidisciplinary approach&#x000a0;is often required&#x000a0;for management, and staging may be more complex than in other diseases with well-defined classification systems.<xref ref-type="bibr" rid="article-151525.r124">[124]</xref></p>
      </sec>
      <sec id="article-151525.s12" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Managing the toxicity and adverse effects of treatment for sympathetic ophthalmia is an important aspect of patient care. Treatment regimens, particularly those involving long-term corticosteroid use and immunosuppressive agents, can lead to various side effects. Here are general strategies for managing such complications:</p>
        <p>
<bold>Corticosteroid-Induced Side Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Osteoporosis prevention</bold>: Calcium, vitamin D supplements, and bone density monitoring</p>
          </list-item>
          <list-item>
            <p><bold>Hyperglycemia control:</bold>&#x000a0;Blood sugar level monitoring and collaborating with a primary care physician for diabetes management</p>
          </list-item>
          <list-item>
            <p><bold>Increased infection risk:</bold>&#x000a0;Educate patients on signs of infection; possibly prescribe prophylactic antibiotics for specific situations</p>
          </list-item>
          <list-item>
            <p><bold>Cataract and glaucoma:</bold>&#x000a0;Regular eye examinations, pressure monitoring, and surgeries as needed</p>
          </list-item>
        </list>
        <p>
<bold>Immunosuppressive Drug Monitoring</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Liver and kidney function:</bold>&#x000a0;Regular blood tests to monitor liver enzymes and kidney function due to the potential hepatotoxicity and nephrotoxicity of medications like methotrexate and cyclosporine</p>
          </list-item>
          <list-item>
            <p><bold>Blood dyscrasias:</bold>&#x000a0;Complete blood counts to monitor for anemia, leukopenia, and thrombocytopenia</p>
          </list-item>
          <list-item>
            <p><bold>Infection surveillance:</bold>&#x000a0;Patients on immunosuppressive therapy are more susceptible to opportunistic infections&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Biologic Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Injection site reactions:</bold>&#x000a0;Local care and possibly adjusting the administration technique</p>
          </list-item>
          <list-item>
            <p><bold>Risk of reactivation of tuberculosis</bold>: Screening for tuberculosis before starting therapy with biologic agents, particularly TNF-&#x003b1; inhibitors</p>
          </list-item>
          <list-item>
            <p><bold>Demyelinating disorders:</bold>&#x000a0;Neurological assessment for any new-onset neurological symptoms</p>
          </list-item>
        </list>
        <p>
<bold>General Health Maintenance</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Nutritional support:</bold>&#x000a0;A balanced diet may help manage weight and maintain overall health.</p>
          </list-item>
          <list-item>
            <p><bold>Physical activity:</bold>&#x000a0;Encourage weight-bearing exercises to maintain bone density and muscle strength.</p>
          </list-item>
          <list-item>
            <p><bold>Psychosocial support:</bold>&#x000a0;Access to mental health professionals to address any psychological effects of chronic illness and vision loss is&#x000a0;important.</p>
          </list-item>
        </list>
        <p>
<bold>Patient Education</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Medication adherence:</bold>&#x000a0;Stress the importance of not abruptly stopping medications to avoid acute rebound effects.</p>
          </list-item>
          <list-item>
            <p><bold>Adverse&#x000a0;effect awareness:</bold>&#x000a0;Educate patients about potential&#x000a0;adverse&#x000a0;effects and when to seek medical help.</p>
          </list-item>
        </list>
        <p>Treating clinicians must&#x000a0;tailor management plans based on the specific medications used and the patient&#x02019;s overall health profile. Regular and comprehensive monitoring for side effects can mitigate the risks associated with treating sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r125">[125]</xref><xref ref-type="bibr" rid="article-151525.r126">[126]</xref><xref ref-type="bibr" rid="article-151525.r127">[127]</xref><xref ref-type="bibr" rid="article-151525.r128">[128]</xref><xref ref-type="bibr" rid="article-151525.r129">[129]</xref></p>
      </sec>
      <sec id="article-151525.s13" sec-type="Staging">
        <title>Staging</title>
        <p>Sympathetic ophthalmia does not have a universally accepted staging system like some other diseases, largely due to&#x000a0;its rarity. However, the clinical presentation of the disease can be described in terms of&#x000a0;the severity and the extent of ocular involvement. A potential approach to staging could consider the following factors:</p>
        <p>
<bold>Onset of Symptoms</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acute</bold>: The sudden appearance of symptoms following trauma or surgery to the fellow eye, typically within days to months.</p>
          </list-item>
          <list-item>
            <p><bold>Delayed:</bold> Symptoms manifesting months to years after the inciting event&#x000a0;<xref ref-type="bibr" rid="article-151525.r3">[3]</xref><xref ref-type="bibr" rid="article-151525.r118">[118]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Clinical Features</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mild:</bold> Mild uveitis with slight discomfort, minimal visual impairment, and few inflammatory signs</p>
          </list-item>
          <list-item>
            <p><bold>Moderate:</bold> More pronounced uveitis with moderate pain and visual impairment, keratitic precipitates, and vitreous haze.</p>
          </list-item>
          <list-item>
            <p><bold>Severe:</bold> Intense inflammation with significant pain, photophobia, severe vision loss, and the presence of exudative retinal detachments or choroidal neovascularization.<xref ref-type="bibr" rid="article-151525.r119">[119]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Anatomical Involvement</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Anterior uveitis:</bold> Inflammation primarily in the iris and ciliary body</p>
          </list-item>
          <list-item>
            <p><bold>Intermediate uveitis</bold>: Inflammation centered in the vitreous</p>
          </list-item>
          <list-item>
            <p><bold>Posterior uveitis:</bold> Inflammation affecting the retina and choroid</p>
          </list-item>
          <list-item>
            <p><bold>Panuveitis:</bold> Involvement of all segments of the uvea&#x000a0;<xref ref-type="bibr" rid="article-151525.r120">[120]</xref></p>
          </list-item>
        </list>
        <p>
<bold>&#x000a0;The Extent</bold>
<bold>&#x000a0;of Systemic Immune Response</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Localized:</bold> Inflammation confined to the eyes with no systemic immune reaction</p>
          </list-item>
          <list-item>
            <p><bold>Systemic:</bold> Evidence of a more generalized autoimmune response potentially affecting other organs&#x000a0;<xref ref-type="bibr" rid="article-151525.r121">[121]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage I:</bold> No complications, inflammation controlled with medication</p>
          </list-item>
          <list-item>
            <p><bold>Stage II:</bold> Development of complications such as cataracts or glaucoma, controllable with treatment</p>
          </list-item>
          <list-item>
            <p><bold>Stage III:</bold> Complications such as chronic cystoid macular edema, optic atrophy, or subretinal neovascular membranes leading to irreversible vision loss&#x000a0;<xref ref-type="bibr" rid="article-151525.r122">[122]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Response to Treatment</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Responsive:</bold>&#x000a0;The disease responds to initial therapy without recurrence</p>
          </list-item>
          <list-item>
            <p><bold>Refractory:</bold> Disease not adequately controlled with standard therapy, requiring more aggressive treatment or resulting in chronic condition&#x000a0;<xref ref-type="bibr" rid="article-151525.r123">[123]</xref></p>
          </list-item>
        </list>
        <p>This&#x000a0;staging is not officially recognized and is more for descriptive purposes, as clinicians often tailor treatment to the individual patient&#x02019;s condition rather than a specific stage. Due to the variability of the disease, a multidisciplinary approach is often required for management, and staging may be more complex than in other diseases with well-defined classification systems.<xref ref-type="bibr" rid="article-151525.r124">[124]</xref></p>
      </sec>
      <sec id="article-151525.s14" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Early initiation of immunomodulatory therapy is&#x000a0;key&#x000a0;for improving visual outcomes in patients with sympathetic ophthalmia. Studies show that the initiation of treatment within 15 days of symptom onset&#x000a0;caused over 85% of sympathizing eyes to achieve visual acuity of 20/40 or better and over 20% of&#x000a0;inciting eyes to reach at least 20/80.&#x000a0;However, given the relapsing nature of this disease, patients need lifelong follow-up to avoid vision-threatening complications.<xref ref-type="bibr" rid="article-151525.r82">[82]</xref><xref ref-type="bibr" rid="article-151525.r97">[97]</xref>&#x000a0;The prognosis of sympathetic ophthalmia&#x000a0;varies significantly and largely depends on how quickly and effectively the inflammation is controlled. Here are several factors that can impact the prognosis:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Timing of treatment:&#x000a0;</bold>Early diagnosis and prompt treatment initiation are crucial for a better prognosis. Delayed treatment can lead to irreversible ocular damage.</p>
          </list-item>
          <list-item>
            <p><bold>Severity of inflammation:&#x000a0;</bold>The severity of inflammation at the time of presentation is a&#x000a0;key&#x000a0;determinant. More severe inflammation is associated with a poorer prognosis.</p>
          </list-item>
          <list-item>
            <p><bold>Response to treatment:&#x000a0;</bold>A&#x000a0;positive response to steroids and immunosuppressive therapy can help preserve vision and improve the long-term prognosis.</p>
          </list-item>
          <list-item>
            <p><bold>Complications:&#x000a0;</bold>The development of complications such as cataracts, glaucoma, or subretinal neovascularization can worsen the prognosis. Management of these complications is an essential part of improving the overall outcome.</p>
          </list-item>
          <list-item>
            <p><bold>Recurrence:&#x000a0;</bold>Recurrent episodes of inflammation can lead to cumulative damage to the eye, resulting in a poorer visual prognosis.</p>
          </list-item>
          <list-item>
            <p><bold>Systemic disease:&#x000a0;</bold>If sympathetic ophthalmia is associated with systemic autoimmune disorders, managing the overall systemic condition is also necessary for a better prognosis.</p>
          </list-item>
          <list-item>
            <p><bold>Adherence to treatment plan:&#x000a0;</bold>Patient adherence to a long-term treatment plan, including systemic medications with potential side effects, is crucial for maintaining disease control and improving outcomes.<xref ref-type="bibr" rid="article-151525.r62">[62]</xref><xref ref-type="bibr" rid="article-151525.r129">[129]</xref><xref ref-type="bibr" rid="article-151525.r130">[130]</xref><xref ref-type="bibr" rid="article-151525.r131">[131]</xref><xref ref-type="bibr" rid="article-151525.r132">[132]</xref><xref ref-type="bibr" rid="article-151525.r133">[133]</xref><xref ref-type="bibr" rid="article-151525.r134">[134]</xref></p>
          </list-item>
        </list>
        <p>Despite these considerations, modern immunosuppressive treatments have improved the prognosis of sympathetic ophthalmia compared to the pre-steroid era. However, due to the potential for chronicity and recurrence, some patients may experience a decline in visual function over time.&#x000a0;Current research and newer therapies continue to&#x000a0;facilitate&#x000a0;improvements in the management and prognosis. Regular follow-up with an ophthalmologist and, when appropriate, a rheumatologist or immunologist is essential.</p>
      </sec>
      <sec id="article-151525.s15" sec-type="Complications">
        <title>Complications</title>
        <p>The most common complications seen with sympathetic ophthalmia are cataract development and ocular hypertension, leading to glaucoma.<xref ref-type="bibr" rid="article-151525.r29">[29]</xref>&#x000a0;Cataract development can result from recurrent or persistent intraocular inflammation and long-term corticosteroid therapy. Cataract extraction for patients with sympathetic ophthalmia is safe with meticulous surgical planning and careful preoperative and postoperative management of intraocular inflammation.<xref ref-type="bibr" rid="article-151525.r135">[135]</xref>&#x000a0;However, final visual acuity depends on the extent of the patient&#x02019;s posterior segment disease. Ocular hypertension can occur in acute inflammation causing&#x000a0;trabeculitis&#x000a0;or in the chronic setting secondary to extensive peripheral anterior synechiae formation or pupillary block secondary to posterior synechiae.<xref ref-type="bibr" rid="article-151525.r136">[136]</xref></p>
        <p>Chronic serous retinal detachments can lead to subretinal fibrosis, severely compromising vision if the macula is involved. Compromised choroid and&#x000a0;retinal pigment epithelium&#x000a0;can lead to choroidal neovascularization, which may require anti-vascular endothelial growth factor intravitreal injections.<xref ref-type="bibr" rid="article-151525.r137">[137]</xref>&#x000a0;Bevacizumab, ranibizumab, or aflibercept are equally appropriate for treating&#x000a0;choroidal neovascularization&#x000a0;in patients with sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r3">[3]</xref>&#x000a0;Other potential side effects of chronic disease include choroidal atrophy and phthisis.<xref ref-type="bibr" rid="article-151525.r4">[4]</xref>&#x000a0;Sympathetic ophthalmia can lead to several severe ocular complications, some threatening vision. The complications are often a result of the underlying inflammatory process or the side effects of the intensive treatments required to control the disease. Common complications include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Glaucoma:&#x000a0;</bold>Increased intraocular pressure can lead to glaucoma either due to the disease or as a side effect of steroid therapy.</p>
          </list-item>
          <list-item>
            <p><bold>Macular edema:&#x000a0;</bold>Inflammation can cause fluid accumulation in the retina, particularly in the macula, leading to cystoid macular edema, impairing central vision.</p>
          </list-item>
          <list-item>
            <p><bold>Choroidal neovascularization:&#x000a0;</bold>Abnormal blood vessel growth under the retina, stimulated by chronic inflammation, can cause bleeding and scarring, threatening vision.</p>
          </list-item>
          <list-item>
            <p><bold>Optic atrophy:&#x000a0;</bold>Prolonged inflammation can damage the optic nerve, leading to optic atrophy and permanent vision loss.</p>
          </list-item>
          <list-item>
            <p><bold>Band keratopathy:&#x000a0;</bold>Deposition of calcium in the cornea can occur as a chronic response to inflammation.</p>
          </list-item>
          <list-item>
            <p><bold>Epiretinal membrane formation:&#x000a0;</bold>Scar tissue may form on the retina&#x02019;s surface, distorting vision.</p>
          </list-item>
          <list-item>
            <p><bold>Scleral and corneal thinning:&#x000a0;</bold>Chronic inflammation can lead to the thinning of the sclera and cornea, potentially leading to structural weaknesses.</p>
          </list-item>
          <list-item>
            <p><bold>Uveitic glaucoma:&#x000a0;</bold>A specific type of glaucoma that arises due to uveitis can be&#x000a0;difficult&#x000a0;to manage because the eye is already compromised.</p>
          </list-item>
          <list-item>
            <p><bold>Phthisis bulbi:&#x000a0;</bold>In severe, end-stage cases, the eye&#x000a0;is atrophic, shrunken, and non-functional.<xref ref-type="bibr" rid="article-151525.r138">[138]</xref><xref ref-type="bibr" rid="article-151525.r139">[139]</xref><xref ref-type="bibr" rid="article-151525.r140">[140]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151525.s16" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Postoperative and rehabilitation care for patients with sympathetic ophthalmia is multifaceted. The care&#x000a0;is designed&#x000a0;to manage the inflammation, prevent recurrence, address complications, and aid the patient in adapting to any visual changes. Here are some of the critical components of postoperative and rehabilitation care:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Medication management:&#x000a0;</bold>Adjusting and monitoring immunosuppressive medications to manage inflammation without causing significant side effects</p>
          </list-item>
          <list-item>
            <p><bold>Slow and careful tapering of corticosteroids:&#x000a0;</bold>Using topical anti-inflammatory medications as needed to control ocular surface inflammation</p>
          </list-item>
          <list-item>
            <p><bold>Monitoring for complications:&#x000a0;</bold>Regular ophthalmic exams to detect and treat cataracts, glaucoma, macular edema, or retinal detachments (and monitoring intraocular pressure and adjusting glaucoma medications as needed)</p>
          </list-item>
          <list-item>
            <p><bold>Visual rehabilitation:&#x000a0;</bold>Low vision aids and adaptive technologies to help patients maximize their remaining vision</p>
          </list-item>
          <list-item>
            <p><bold>Referral to low vision specialists for rehabilitation strategies:&#x000a0;</bold>Orientation and mobility training for patients with significant vision loss</p>
          </list-item>
          <list-item>
            <p><bold>Patient education:&#x000a0;</bold>Teaching patients about the signs of infection, inflammation, or increased intraocular pressure should prompt immediate medical attention and&#x000a0;provide&#x000a0;information on the chronic nature of&#x000a0;sympathetic ophthalmia&#x000a0;and the importance of adhering to follow-up schedules and medication regimens</p>
          </list-item>
          <list-item>
            <p><bold>Physical and occupational therapy:&#x000a0;</bold>If vision loss is significant, physical and occupational therapy&#x000a0;is necessary to assist the patient in adapting to changes in vision and maintaining independence</p>
          </list-item>
          <list-item>
            <p><bold>Psychological support:&#x000a0;</bold>Psychological or psychiatric support to address issues such as depression or anxiety that can accompany chronic illness and vision loss and&#x000a0;connect&#x000a0;patients with support groups and other resources for&#x000a0;visual impairment.</p>
          </list-item>
          <list-item>
            <p><bold>Lifestyle adjustments:&#x000a0;</bold>Counseling on ultraviolet protection to reduce further ocular damage and nutritional guidance to support overall eye health</p>
          </list-item>
          <list-item>
            <p><bold>Systemic health maintenance:&#x000a0;</bold>Collaborating with primary care physicians and other specialists to manage comorbid conditions and the systemic side effects of long-term immunosuppression</p>
          </list-item>
          <list-item>
            <p><bold>Surgical interventions:&#x000a0;</bold>Planning for any additional surgeries that may be necessary due to complications such as cataracts or glaucoma</p>
          </list-item>
          <list-item>
            <p><bold>Documentation and communication:&#x000a0;</bold>Keeping detailed medical records to document the patient&#x02019;s progress and responses to treatment and ensuring clear communication between all healthcare team members, including the patient and family&#x000a0;<xref ref-type="bibr" rid="article-151525.r130">[130]</xref><xref ref-type="bibr" rid="article-151525.r141">[141]</xref><xref ref-type="bibr" rid="article-151525.r142">[142]</xref><xref ref-type="bibr" rid="article-151525.r143">[143]</xref><xref ref-type="bibr" rid="article-151525.r144">[144]</xref><xref ref-type="bibr" rid="article-151525.r145">[145]</xref><xref ref-type="bibr" rid="article-151525.r146">[146]</xref></p>
          </list-item>
        </list>
        <p>Effective postoperative and rehabilitation care requires a coordinated effort among ophthalmologists, primary care physicians, rehabilitation specialists, mental health professionals, and the patient and their family or caregivers. This comprehensive approach is essential to achieving the best possible outcome for patients with sympathetic ophthalmia.</p>
      </sec>
      <sec id="article-151525.s17" sec-type="Consultations">
        <title>Consultations</title>
        <p>Here are the consultations that might be required:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Ophthalmologist:&#x000a0;</bold>A comprehensive evaluation by an ophthalmologist is essential.&#x000a0;This&#x000a0;may include an anterior segment surgeon, a vitreoretinal specialist, and a uveitis specialist.</p>
          </list-item>
          <list-item>
            <p><bold>Rheumatologist or immunologist:&#x000a0;</bold>These professionals manage immunosuppressive therapy and monitor&#x000a0;for systemic autoimmune responses.</p>
          </list-item>
          <list-item>
            <p><bold>Infectious disease:&#x000a0;</bold>Assess the risk of reactivating latent infections like tuberculosis before initiating immunosuppressive therapy, particularly with biological agents.</p>
          </list-item>
          <list-item>
            <p><bold>Endocrinologist:&#x000a0;</bold>If the patient is on long-term corticosteroids, an endocrinologist can help manage steroid-induced side effects such as diabetes, osteoporosis, and adrenal insufficiency.</p>
          </list-item>
          <list-item>
            <p><bold>Glaucoma specialist:&#x000a0;</bold>These specialists manage&#x000a0;increased intraocular pressure secondary to or a side effect of corticosteroid therapy.</p>
          </list-item>
          <list-item>
            <p><bold>Neurologist:&#x000a0;</bold>A neurologist may be helpful if neurological symptoms occur, especially considering that&#x000a0;sympathetic ophthalmia&#x000a0;is associated with other autoimmune conditions that affect the central nervous system.</p>
          </list-item>
          <list-item>
            <p><bold>Low vision specialist:&#x000a0;</bold>These specialists assist with visual rehabilitation and using aids and adaptive devices.</p>
          </list-item>
          <list-item>
            <p><bold>Occupational therapist:&#x000a0;</bold>This therapist helps the patient adapt to changes in vision and maintain independence in daily activities.</p>
          </list-item>
          <list-item>
            <p><bold>Psychologist or psychiatrist: </bold>A psychologist or psychiatrist may help support the psychological impact of chronic illness and potential vision loss.</p>
          </list-item>
          <list-item>
            <p><bold>Social worker:&#x000a0;</bold>Social workers assist with healthcare navigation and access to community resources and support systems.</p>
          </list-item>
          <list-item>
            <p><bold>Physical therapist:&#x000a0;</bold>If severe vision loss affects mobility, a physical therapist can help develop new strategies for safe movement and independence.</p>
          </list-item>
          <list-item>
            <p><bold>Nutritionist:&#x000a0;</bold>A nutritionist can provide dietary advice that may help manage medication side effects and overall health.</p>
          </list-item>
          <list-item>
            <p><bold>Pain management specialist: </bold>A pain management specialist may be necessary if the patient experiences chronic pain related to sympathetic ophthalmia or the treatment.</p>
          </list-item>
          <list-item>
            <p><bold>Primary care physician: </bold>The primary care physician coordinates care, manages comorbidities, and monitors the patient&#x02019;s health during treatment.<xref ref-type="bibr" rid="article-151525.r147">[147]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151525.s18" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Sympathetic ophthalmia is a severe bilateral uveitis resulting in permanent vision loss if appropriate therapy&#x000a0;is not initiated&#x000a0;immediately. Patients who have suffered any traumatic ocular injury should&#x000a0;be counseled&#x000a0;on the potential risk of this condition, especially within the first year of injury.&#x000a0;Patients should contact&#x000a0;their ophthalmologist or go to the nearest emergency room if&#x000a0;they experience pain, redness, or vision loss in either eye.<xref ref-type="bibr" rid="article-151525.r3">[3]</xref>&#x000a0;Clinicians&#x000a0;of higher-risk intraocular surgery, such as vitreoretinal surgeons, should also consider discussing the risks of sympathetic ophthalmia with their patients. Given that the inflammation in sympathetic ophthalmia may be chronic and relapsing, patients should also&#x000a0;be educated&#x000a0;on recognizing signs and symptoms of recurrence, including worsening vision, photophobia, eye pain, redness, and irritation.<xref ref-type="bibr" rid="article-151525.r7">[7]</xref>&#x000a0;Patient education for sympathetic ophthalmia is paramount and involves several key points:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Understanding the condition</bold>: Patients should be educated about the disease&#x02019;s autoimmune nature, its effect on both eyes, and the importance of monitoring for symptoms,&#x000a0;though&#x000a0;only&#x000a0;1&#x000a0;eye is initially injured.</p>
          </list-item>
          <list-item>
            <p><bold>Preventive measures:&#x000a0;</bold>Patients&#x000a0;should be informed about the importance of wearing protective eyewear to prevent ocular trauma, a risk factor for developing the condition.</p>
          </list-item>
          <list-item>
            <p><bold>Symptom awareness: </bold>It is vital to educate patients on symptoms, such as the sudden onset of vision loss, pain, or redness, that necessitate immediate medical attention.</p>
          </list-item>
          <list-item>
            <p><bold>Importance of follow-up</bold>: Regular follow-up visits are essential to monitor the effectiveness of therapy and make any necessary adjustments.</p>
          </list-item>
          <list-item>
            <p><bold>Medication adherence: </bold>It is important to adhere to prescribed medication regimens, even though symptoms improve, to prevent relapses.</p>
          </list-item>
          <list-item>
            <p><bold>Managing adverse events:&#x000a0;</bold>This section provides information on possible side effects of treatments, particularly corticosteroids and immunosuppressants, and when to contact a&#x000a0;clinician if these occur.</p>
          </list-item>
          <list-item>
            <p><bold>Long-term management:&#x000a0;</bold>This&#x000a0;includes understanding that this condition may require long-term or lifelong management and highlighting the importance of maintaining a relationship with treating clinicians.</p>
          </list-item>
          <list-item>
            <p><bold>Support resources:&#x000a0;</bold>Providing resources for support groups or counseling services to help patients cope with the emotional and psychological impact of chronic disease and potential vision loss.<xref ref-type="bibr" rid="article-151525.r148">[148]</xref><xref ref-type="bibr" rid="article-151525.r149">[149]</xref><xref ref-type="bibr" rid="article-151525.r150">[150]</xref></p>
          </list-item>
        </list>
        <p>Ensure that patients with sympathetic ophthalmia are well-informed about their condition and its management. This makes them active participants, leading to better outcomes and a reduced risk of complications.</p>
      </sec>
      <sec id="article-151525.s19" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>In managing sympathetic ophthalmia, depth of knowledge and vigilance are crucial:</p>
        <p>
<bold>Pearls</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Swift intervention following ocular trauma or surgery can significantly alter prognosis.</p>
          </list-item>
          <list-item>
            <p>Sympathetic ophthalmia can masquerade as other forms of uveitis, so a thorough history is imperative.</p>
          </list-item>
        </list>
        <p>
<bold>Disposition</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lifelong monitoring may be necessary, as the disease can recur after quiescence.</p>
          </list-item>
          <list-item>
            <p>Patients often require a team for management, including ophthalmologists, rheumatologists, and potentially immunologists.</p>
          </list-item>
        </list>
        <p>
<bold>Pitfalls</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Delay in treatment or misdiagnosis can lead to a cascade of ocular complications and vision loss.</p>
          </list-item>
          <list-item>
            <p>Insufficient dosing or early cessation of immunosuppressive therapy can result in disease flares.</p>
          </list-item>
        </list>
        <p>
<bold>Prevention</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prompt and appropriate management of ocular injuries and informed decision-making regarding enucleation in specific cases can reduce risk.</p>
          </list-item>
          <list-item>
            <p>Preoperative patient education on the risks of elective intraocular surgery is crucial.</p>
          </list-item>
        </list>
        <p>
<bold>Additional Considerations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Counseling on the chronicity of the disease and the commitment to long-term treatment is essential.</p>
          </list-item>
          <list-item>
            <p>Developing an individualized plan for medication management, considering comorbidities and the risk of systemic side effects, enhances patient adherence and outcomes.<xref ref-type="bibr" rid="article-151525.r7">[7]</xref><xref ref-type="bibr" rid="article-151525.r9">[9]</xref><xref ref-type="bibr" rid="article-151525.r151">[151]</xref><xref ref-type="bibr" rid="article-151525.r152">[152]</xref><xref ref-type="bibr" rid="article-151525.r153">[153]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-151525.s20" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Sympathetic ophthalmia&#x000a0;is a clinical diagnosis requiring a carefully detailed history and physical exam to parse out the diagnosis from potential masqueraders. Ophthalmologists almost always care for patients with sudden eye pain or vision loss. Still, they may not be the first&#x000a0;clinician to&#x000a0;evaluate the patient. Nurses, optometrists, and emergency medicine clinicians need a baseline understanding of this&#x000a0;disease and when&#x000a0;to refer for subspecialty care. The patient also requires an interprofessional team&#x000a0;that includes&#x000a0;internal medicine clinicians and pharmacists to co-manage&#x000a0;their disease, given the need for long-term steroid&#x000a0;use or immunomodulation. Enhancing healthcare outcomes for patients with sympathetic ophthalmia demands a collaborative, multi-disciplinary approach:</p>
        <p>
<bold>Physicians and Ophthalmologists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Lead the diagnosis and management plan</p>
          </list-item>
          <list-item>
            <p>Regularly evaluate treatment efficacy and adjust as needed</p>
          </list-item>
        </list>
        <p>
<bold>Rheumatologists or Immunologists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Assist with systemic immunosuppression</p>
          </list-item>
          <list-item>
            <p>Monitor for side effects of treatments</p>
          </list-item>
        </list>
        <p>
<bold>Nurses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Provide patient education and post-treatment care instructions</p>
          </list-item>
          <list-item>
            <p>Monitor for signs of complications or side effects from medication</p>
          </list-item>
        </list>
        <p>
<bold>Pharmacists</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Manage and advise on medication interactions</p>
          </list-item>
          <list-item>
            <p>Counsel patients on proper medication usage and potential side effects</p>
          </list-item>
        </list>
        <p>
<bold>Ethics and Strategy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ensure informed consent&#x000a0;is obtained, especially when discussing the risks of bilateral eye involvement.</p>
          </list-item>
          <list-item>
            <p>Maintain patient confidentiality and autonomy in the management&#x000a0;plan</p>
          </list-item>
        </list>
        <p>
<bold>Communication and Coordination</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Use clear, consistent communication across the care team.</p>
          </list-item>
          <list-item>
            <p>Establish a protocol for emergencies related to sudden vision changes or flare-ups.</p>
          </list-item>
        </list>
        <p>
<bold>Patient Safety and Outcomes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Educate patients on signs of disease progression and when to seek immediate care.</p>
          </list-item>
          <list-item>
            <p>Implement safety checks to prevent medication errors.</p>
          </list-item>
        </list>
        <p>
<bold>Team Performance</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hold regular team meetings to discuss patient progress and coordinate care.</p>
          </list-item>
          <list-item>
            <p>Provide continuous education on the latest research and treatments for sympathetic ophthalmia.</p>
          </list-item>
        </list>
        <p>Overall, each team member ensures comprehensive care, from prevention and early intervention to long-term management and monitoring of sympathetic ophthalmia.<xref ref-type="bibr" rid="article-151525.r3">[3]</xref><xref ref-type="bibr" rid="article-151525.r154">[154]</xref><xref ref-type="bibr" rid="article-151525.r155">[155]</xref><xref ref-type="bibr" rid="article-151525.r156">[156]</xref><xref ref-type="bibr" rid="article-151525.r157">[157]</xref><xref ref-type="bibr" rid="article-151525.r158">[158]</xref><xref ref-type="bibr" rid="article-151525.r159">[159]</xref><xref ref-type="bibr" rid="article-151525.r160">[160]</xref></p>
      </sec>
      <sec id="article-151525.s21">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=151525&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=151525">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/sympathetic-ophthalmia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=151525">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/151525/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=151525">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-151525.s22">
        <title>References</title>
        <ref id="article-151525.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <collab>Standardization of Uveitis Nomenclature (SUN) Working Group</collab>
            <article-title>Classification Criteria for Sympathetic Ophthalmia.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>228</volume>
            <fpage>212</fpage>
            <page-range>212-219</page-range>
            <pub-id pub-id-type="pmid">33845005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaharia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lamarche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laurin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic uveitis 66 years after injury.</article-title>
            <source>Can J Ophthalmol</source>
            <year>1984</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>240</fpage>
            <page-range>240-3</page-range>
            <pub-id pub-id-type="pmid">6478310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parchand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ayyadurai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gangwe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Behera</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mulkutkar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barwar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia: A comprehensive update.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>1931</fpage>
            <page-range>1931-1944</page-range>
            <pub-id pub-id-type="pmid">35647958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulbuddhe</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Addya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic Ophthalmia: Where Do We Currently Stand on Treatment Strategies?</article-title>
            <source>Clin Ophthalmol</source>
            <year>2021</year>
            <volume>15</volume>
            <fpage>4201</fpage>
            <page-range>4201-4218</page-range>
            <pub-id pub-id-type="pmid">34707340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Yan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <chapter-title>Sympathetic Ophthalmia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">36943969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Hashmi</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Conjunctivitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">31082078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arevalo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Al-Dhibi</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Suarez-Tata</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Update on sympathetic ophthalmia.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-21</page-range>
            <pub-id pub-id-type="pmid">22346110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Petrillo</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Giani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marrani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Filippeschi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oranges</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Simonini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cimaz</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical Use and Molecular Action of Corticosteroids in the Pediatric Age.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Jan</month>
            <day>21</day>
            <volume>20</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30669566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mahan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purt</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Ocular Trauma Prevention Strategies and Patient Counseling</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">35593844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albert</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Diaz-Rohena</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A historical review of sympathetic ophthalmia and its epidemiology.</article-title>
            <source>Surv Ophthalmol</source>
            <year>1989</year>
            <season>Jul-Aug</season>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">2678549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kilmartin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Forrester</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>84</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-63</page-range>
            <pub-id pub-id-type="pmid">10684834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Chee</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia in Singapore: new trends in an old disease.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>244</volume>
            <issue>2</issue>
            <fpage>243</fpage>
            <page-range>243-7</page-range>
            <pub-id pub-id-type="pmid">16028023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brour</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Desjardins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lehoang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lumbroso-Lerouic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dendale</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cassoux</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia after proton beam irradiation for choro&#x000ef;dal melanoma.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>273</fpage>
            <page-range>273-6</page-range>
            <pub-id pub-id-type="pmid">22646709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albahlal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Dhibi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Al Shahwan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khandekar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Edward</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia following diode laser cyclophotocoagulation.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>98</volume>
            <issue>8</issue>
            <fpage>1101</fpage>
            <page-range>1101-6</page-range>
            <pub-id pub-id-type="pmid">24711656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brouzas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koutsandrea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moschos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papadimitriou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ladas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Apostolopoulos</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Massive choroidal hemorrhage after intravitreal administration of bevacizumab (Avastin) for AMD followed by controlateral sympathetic ophthalmia.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2009</year>
            <volume>3</volume>
            <fpage>457</fpage>
            <page-range>457-9</page-range>
            <pub-id pub-id-type="pmid">19714263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Okoye</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <chapter-title>Traumatic Cataract</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">37603642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parmar</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meena</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mutha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Corset suture: A novel technique of overlay appositional continuous sutures with air tamponade for management of large acute corneal hydrops.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2024</year>
            <month>Apr</month>
            <day>01</day>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>592</fpage>
            <page-range>592-595</page-range>
            <pub-id pub-id-type="pmid">38546470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mohseni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bragg</surname>
                <given-names>BN</given-names>
              </name>
            </person-group>
            <chapter-title>Blunt Eye Trauma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">29261988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Manual small-incision cataract surgery - A stepping stone toward self-independent cataract surgeons.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2024</year>
            <month>Jan</month>
            <day>01</day>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>140</fpage>
            <pub-id pub-id-type="pmid">38131590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Penetrating Keratoplasty</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">37276324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Intricate clinical evaluation and management strategies in vision-threatening phacomorphic glaucoma.</article-title>
            <source>Taiwan J Ophthalmol</source>
            <year>2023</year>
            <season>Apr-Jun</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-260</page-range>
            <pub-id pub-id-type="pmid">37484623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonugunta</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Radhakrishnan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lalitha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Keenan</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Prajna</surname>
                <given-names>NV</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of Pythium keratitis: a meta-analysis of individual patient data.</article-title>
            <source>Curr Ophthalmol Rep</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>198</fpage>
            <page-range>198-208</page-range>
            <pub-id pub-id-type="pmid">37250102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mahabadi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Edens</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <chapter-title>Iritis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">28613659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Tips to prevent inadvertent stromal staining and Descemet membrane detachment while performing paracentesis during cataract surgery.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2023</year>
            <month>May</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>2300</fpage>
            <page-range>2300-2301</page-range>
            <pub-id pub-id-type="pmid">37202984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radosavljevic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tyagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pichi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Al Dhanhani</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>ET</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic Ophthalmia - An Overview.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2023</year>
            <month>May</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>793</fpage>
            <page-range>793-809</page-range>
            <pub-id pub-id-type="pmid">35579612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tanya</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kezouh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torun</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ing</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The Incidence of Sympathetic Ophthalmia After Trauma: A Meta-analysis.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>234</volume>
            <fpage>117</fpage>
            <page-range>117-125</page-range>
            <pub-id pub-id-type="pmid">34283983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reddy Pappuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Dedhia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Panchal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaza</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pathengay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sangwan</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic Ophthalmia after Vitreoretinal Surgeries: Incidence, Clinical Presentations and Outcomes of a Rare Disease.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2019</year>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>157</fpage>
            <page-range>157-162</page-range>
            <pub-id pub-id-type="pmid">31055985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hashimoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Michihata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ishimaru</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yasunaga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aihara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaburaki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Incidence of Sympathetic Ophthalmia after Inciting Events: A National Database Study in Japan.</article-title>
            <source>Ophthalmology</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>344</fpage>
            <page-range>344-352</page-range>
            <pub-id pub-id-type="pmid">34560127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Feuer</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Dubovy</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Setlur</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kesen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Tessler</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Ganelis</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Jabs</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia: incidence of ocular complications and vision loss in the sympathizing eye.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>148</volume>
            <issue>5</issue>
            <fpage>704</fpage>
            <page-range>704-710.e2</page-range>
            <pub-id pub-id-type="pmid">19665105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dogra</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Posterior sympathetic ophthalmia: a single centre long-term study of 40 patients from North India.</article-title>
            <source>Eye (Lond)</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>12</issue>
            <fpage>1459</fpage>
            <page-range>1459-64</page-range>
            <pub-id pub-id-type="pmid">17618240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutta Majumder</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anthony</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Ganesh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Postsurgical sympathetic ophthalmia: retrospective analysis of a rare entity.</article-title>
            <source>Int Ophthalmol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>2487</fpage>
            <page-range>2487-2493</page-range>
            <pub-id pub-id-type="pmid">29164454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HOLLAND</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[INDICATION AND TIMING OF THE REMOVAL OF AN INJURED EYE].</article-title>
            <source>Klin Monbl Augenheilkd</source>
            <year>1964</year>
            <month>Nov</month>
            <volume>145</volume>
            <fpage>732</fpage>
            <page-range>732-40</page-range>
            <pub-id pub-id-type="pmid">14338820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aida</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawachi</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Gender differences in risk of posttraumatic stress symptoms after disaster among older people: Differential exposure or differential vulnerability?</article-title>
            <source>J Affect Disord</source>
            <year>2022</year>
            <month>Jan</month>
            <day>15</day>
            <volume>297</volume>
            <fpage>447</fpage>
            <page-range>447-454</page-range>
            <pub-id pub-id-type="pmid">34715197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu El-Asrar</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Struyf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van den Broeck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Van Damme</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Opdenakker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Geboes</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kestelyn</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Expression of chemokines and gelatinase B in sympathetic ophthalmia.</article-title>
            <source>Eye (Lond)</source>
            <year>2007</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>649</fpage>
            <page-range>649-57</page-range>
            <pub-id pub-id-type="pmid">16601741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Caspi</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Ocular immune privilege.</article-title>
            <source>F1000 Biol Rep</source>
            <year>2010</year>
            <month>Jan</month>
            <day>18</day>
            <volume>2</volume>
            <pub-id pub-id-type="pmid">20948803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Seen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dutta Majumder</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ganesh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mahendradas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Teoh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pavesio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Analysis of 130 Cases of Sympathetic Ophthalmia - A Retrospective Multicenter Case Series.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2019</year>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>1259</fpage>
            <page-range>1259-1266</page-range>
            <pub-id pub-id-type="pmid">30207811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Marak</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>The role of the penetrating wound in the development of sympathetic ophthalmia experimental observations.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1983</year>
            <month>Jan</month>
            <volume>101</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-4</page-range>
            <pub-id pub-id-type="pmid">6849641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Kozak</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thillaye</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Faure</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>S antigen-induced experimental autoimmune uveo-retinitis in rats.</article-title>
            <source>Curr Eye Res</source>
            <year>1981</year>
            <volume>1</volume>
            <issue>6</issue>
            <fpage>327</fpage>
            <page-range>327-37</page-range>
            <pub-id pub-id-type="pmid">6975701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schalken</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Winkens</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Van Vugt</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>De Grip</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Broekhuyse</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Rhodopsin-induced experimental autoimmune uveoretinitis in monkeys.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>168</fpage>
            <page-range>168-72</page-range>
            <pub-id pub-id-type="pmid">2706205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gery</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wiggert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Redmond</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Kuwabara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vistica</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Chader</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-binding protein.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>1986</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>1296</fpage>
            <page-range>1296-300</page-range>
            <pub-id pub-id-type="pmid">3488297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gery</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chanaud</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Anglade</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Recoverin is highly uveitogenic in Lewis rats.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>1994</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>3342</fpage>
            <page-range>3342-5</page-range>
            <pub-id pub-id-type="pmid">8045724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kilmartin</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liversidge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Acheson</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Urbaniak</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Forrester</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>281</fpage>
            <page-range>281-6</page-range>
            <pub-id pub-id-type="pmid">11222331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shindo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Usui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ideta</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Inoko</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Immunogenetic study of sympathetic ophthalmia.</article-title>
            <source>Tissue Antigens</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-5</page-range>
            <pub-id pub-id-type="pmid">9062965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirose</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Palestine</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Wiggert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Redmond</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Chader</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Gery</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Lymphocyte responses to retinal-specific antigens in uveitis patients and healthy subjects.</article-title>
            <source>Curr Eye Res</source>
            <year>1988</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>393</fpage>
            <page-range>393-402</page-range>
            <pub-id pub-id-type="pmid">3371075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenblum</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Remedios</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of human autoimmunity.</article-title>
            <source>J Clin Invest</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>125</volume>
            <issue>6</issue>
            <fpage>2228</fpage>
            <page-range>2228-33</page-range>
            <pub-id pub-id-type="pmid">25893595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sosa</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Forsthuber</surname>
                <given-names>TG</given-names>
              </name>
            </person-group>
            <article-title>The critical role of antigen-presentation-induced cytokine crosstalk in the central nervous system in multiple sclerosis and experimental autoimmune encephalomyelitis.</article-title>
            <source>J Interferon Cytokine Res</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>10</issue>
            <fpage>753</fpage>
            <page-range>753-68</page-range>
            <pub-id pub-id-type="pmid">21919736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Functions and Diseases of the Retinal Pigment Epithelium.</article-title>
            <source>Front Pharmacol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>727870</fpage>
            <pub-id pub-id-type="pmid">34393803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>MAR</given-names>
              </name>
              <name>
                <surname>Sarwar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Imaging of Classic Dal&#x000e9;n Fuchs Nodules in Sympathetic Ophthalmia With Spectral Domain OCT.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>e20876</fpage>
            <pub-id pub-id-type="pmid">35145783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Clinical Features and Possible Origin of Preretinal Deposits in Different Ocular Diseases and Events: A Narrative Review.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>737</fpage>
            <page-range>737-753</page-range>
            <pub-id pub-id-type="pmid">36795322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>A Review of the Various Roles and Participation Levels of B-Cells in Non-Infectious Uveitis.</article-title>
            <source>Front Immunol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>676046</fpage>
            <pub-id pub-id-type="pmid">34054864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Buonfiglio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Voigt</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bachmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Safi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gericke</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Oxidative stress in the eye and its role in the pathophysiology of ocular diseases.</article-title>
            <source>Redox Biol</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>68</volume>
            <fpage>102967</fpage>
            <pub-id pub-id-type="pmid">38006824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kijlstra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>80</volume>
            <fpage>100866</fpage>
            <pub-id pub-id-type="pmid">32422390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Classical pathology of sympathetic ophthalmia presented in a unique case.</article-title>
            <source>Open Ophthalmol J</source>
            <year>2014</year>
            <volume>8</volume>
            <fpage>32</fpage>
            <page-range>32-8</page-range>
            <pub-id pub-id-type="pmid">25067979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Piacentini</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory cellular kinetics in sympathetic ophthalmia a study of 29 traumatized (exciting) eyes.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>1993</year>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-62</page-range>
            <pub-id pub-id-type="pmid">22822781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balamurugan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hasanreisoglu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toy</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Akhter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anuradha</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Anthony</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Interleukins and cytokine biomarkers in uveitis.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>68</volume>
            <issue>9</issue>
            <fpage>1750</fpage>
            <page-range>1750-1763</page-range>
            <pub-id pub-id-type="pmid">32823391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aziz</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Dubovy</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>SYMPATHETIC OPHTHALMIA: Clinicopathologic Correlation in a Consecutive Case Series.</article-title>
            <source>Retina</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1696</fpage>
            <page-range>1696-703</page-range>
            <pub-id pub-id-type="pmid">25719985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croxatto</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Marak</surname>
                <given-names>GE</given-names>
              </name>
            </person-group>
            <article-title>Atypical histopathologic features in sympathetic ophthalmia. A study of a hundred cases.</article-title>
            <source>Int Ophthalmol</source>
            <year>1982</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>129</fpage>
            <page-range>129-35</page-range>
            <pub-id pub-id-type="pmid">7068330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lubin</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sixty-five years of sympathetic ophthalmia. A clinicopathologic review of 105 cases (1913--1978).</article-title>
            <source>Ophthalmology</source>
            <year>1980</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>109</fpage>
            <page-range>109-21</page-range>
            <pub-id pub-id-type="pmid">7383540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reynard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riffenburgh</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Minckler</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Morphological variation of Dal&#x000e9;n-Fuchs nodules in sympathetic ophthalmia.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1985</year>
            <month>Mar</month>
            <volume>69</volume>
            <issue>3</issue>
            <fpage>197</fpage>
            <page-range>197-201</page-range>
            <pub-id pub-id-type="pmid">3978066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bansal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Current approach in the diagnosis and management of panuveitis.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2010</year>
            <season>Jan-Feb</season>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-54</page-range>
            <pub-id pub-id-type="pmid">20029145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The role of CD4<sup>+</sup> T cells in tumor and chronic viral immune responses.</article-title>
            <source>MedComm (2020)</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>e390</fpage>
            <pub-id pub-id-type="pmid">37829505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>XK</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia: to the twenty-first century and beyond.</article-title>
            <source>J Ophthalmic Inflamm Infect</source>
            <year>2013</year>
            <month>Jun</month>
            <day>01</day>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <pub-id pub-id-type="pmid">23724856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paez-Escamilla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caplash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Odden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marroquin</surname>
                <given-names>OC</given-names>
              </name>
              <name>
                <surname>Koscumb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Commiskey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Indermill</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Finkelstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gushchin</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Coca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Friberg</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Eller</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Harwick</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Waxman</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Chhablani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bonhomme</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Prensky</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anetakis</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Martel</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Massicotte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ores</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Girmens</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Sahel</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dansingani</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Westcott</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Errera</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Challenges in posterior uveitis-tips and tricks for the retina specialist.</article-title>
            <source>J Ophthalmic Inflamm Infect</source>
            <year>2023</year>
            <month>Aug</month>
            <day>17</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <pub-id pub-id-type="pmid">37589912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia and Vogt-Koyanagi-Harada syndrome.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>1990</year>
            <season>Fall</season>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>279</fpage>
            <page-range>279-85</page-range>
            <pub-id pub-id-type="pmid">2228475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r65">
          <label>65</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Feroze</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khazaeni</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Steroid-Induced Glaucoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">28613653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keane</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sadda</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Retinal imaging in the twenty-first century: state of the art and future directions.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>121</volume>
            <issue>12</issue>
            <fpage>2489</fpage>
            <page-range>2489-500</page-range>
            <pub-id pub-id-type="pmid">25282252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleischman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Say</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Landers</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Multimodality diagnostic imaging in a case of sympathetic ophthalmia.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>300</fpage>
            <page-range>300-2</page-range>
            <pub-id pub-id-type="pmid">22594960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahajan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Multimodal Imaging in Sympathetic Ophthalmia.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-159</page-range>
            <pub-id pub-id-type="pmid">27960610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meleth</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>HN</given-names>
              </name>
            </person-group>
            <article-title>Use of fundus autofluorescence in the diagnosis and management of uveitis.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2012</year>
            <season>Fall</season>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>45</fpage>
            <page-range>45-54</page-range>
            <pub-id pub-id-type="pmid">22954928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lightman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ismetova</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Talat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tomkins-Netzer</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Role of autofluorescence in inflammatory/infective diseases of the retina and choroid.</article-title>
            <source>J Ophthalmol</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>418193</fpage>
            <pub-id pub-id-type="pmid">24800061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeppieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marsili</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Enaholo</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Shuaibu</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Uwagboe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Salati</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spadea</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Musa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Optical Coherence Tomography (OCT): A Brief Look at the Uses and Technological Evolution of Ophthalmology.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2023</year>
            <month>Dec</month>
            <day>03</day>
            <volume>59</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">38138217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Katoch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <collab>OCTA Study Group</collab>
            </person-group>
            <article-title>BACILLARY LAYER DETACHMENT IN ACUTE VOGT-KOYANAGI-HARADA DISEASE: A Novel Swept-Source Optical Coherence Tomography Analysis.</article-title>
            <source>Retina</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>774</fpage>
            <page-range>774-783</page-range>
            <pub-id pub-id-type="pmid">32833410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muakkassa</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Witkin</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Spectral-domain optical coherence tomography of sympathetic ophthalmia with Dalen-Fuchs nodules.</article-title>
            <source>Ophthalmic Surg Lasers Imaging Retina</source>
            <year>2014</year>
            <season>Nov-Dec</season>
            <volume>45</volume>
            <issue>6</issue>
            <fpage>610</fpage>
            <page-range>610-2</page-range>
            <pub-id pub-id-type="pmid">25347826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jaisankar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Testi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Raman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Choroidal Structural Changes in Sympathetic Ophthalmia on Swept-Source Optical Coherence Tomography.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2021</year>
            <month>Apr</month>
            <day>03</day>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>537</fpage>
            <page-range>537-542</page-range>
            <pub-id pub-id-type="pmid">31743045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behdad</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rahmani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Montahaei</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soheilian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soheilian</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Enhanced depth imaging OCT (EDI-OCT) findings in acute phase of sympathetic ophthalmia.</article-title>
            <source>Int Ophthalmol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>433</fpage>
            <page-range>433-9</page-range>
            <pub-id pub-id-type="pmid">25772275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkins</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Muldoon</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Sidoti</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>"Persistence of Memory" - Multimodal imaging of delayed sympathetic ophthalmia.</article-title>
            <source>Am J Ophthalmol Case Rep</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>27</volume>
            <fpage>101572</fpage>
            <pub-id pub-id-type="pmid">35845745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grewal</surname>
                <given-names>SPS</given-names>
              </name>
              <name>
                <surname>Grewal</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Treatment Response in Sympathetic Ophthalmia as Assessed by Widefield OCT Angiography.</article-title>
            <source>Ophthalmic Surg Lasers Imaging Retina</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>726</fpage>
            <page-range>726-730</page-range>
            <pub-id pub-id-type="pmid">30222810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levison</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Baynes</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lowder</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Choroidal neovascularisation on optical coherence tomography angiography in punctate inner choroidopathy and multifocal choroiditis.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2017</year>
            <month>May</month>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>616</fpage>
            <page-range>616-622</page-range>
            <pub-id pub-id-type="pmid">27539089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spaide</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Waheed</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Sadda</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Staurenghi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Optical coherence tomography angiography.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2018</year>
            <month>May</month>
            <volume>64</volume>
            <fpage>1</fpage>
            <page-range>1-55</page-range>
            <pub-id pub-id-type="pmid">29229445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r80">
          <label>80</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Muraleedharan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Indocyanine Green (ICG) Angiography</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35593804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r81">
          <label>81</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rizzuti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Eye Trauma Imaging</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">34283468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Damico</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia.</article-title>
            <source>Semin Ophthalmol</source>
            <year>2005</year>
            <season>Jul-Sep</season>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>191</fpage>
            <page-range>191-7</page-range>
            <pub-id pub-id-type="pmid">16282154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharp</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pinkerton</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia. Histopathologic and fluorescein angiographic correlation.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1984</year>
            <month>Feb</month>
            <volume>102</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-5</page-range>
            <pub-id pub-id-type="pmid">6696668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Zamir</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dugel</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Sipperley</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Thirkill</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Shabatian</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Progressive subretinal fibrosis and blindness associated with multifocal granulomatous chorioretinitis: A variant of sympathetic ophthalmia.</article-title>
            <source>Ophthalmology</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>109</volume>
            <issue>8</issue>
            <fpage>1527</fpage>
            <page-range>1527-31</page-range>
            <pub-id pub-id-type="pmid">12153806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casella</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Farah</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oguido</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia - histopathological correlation with fluorescein and indocyanine green angiography: case report.</article-title>
            <source>Arq Bras Oftalmol</source>
            <year>2008</year>
            <season>Nov-Dec</season>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>886</fpage>
            <page-range>886-9</page-range>
            <pub-id pub-id-type="pmid">19169528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saatci</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Pa&#x0015f;a</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>S&#x000f6;ylev</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Ko&#x000e7;ak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Durak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kaynak</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia and indocyanine green angiography.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>122</volume>
            <issue>10</issue>
            <fpage>1568</fpage>
            <page-range>1568-9</page-range>
            <pub-id pub-id-type="pmid">15477482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moshfeghi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ferrone</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Indocyanine green angiography findings in sympathetic ophthalmia.</article-title>
            <source>Ophthalmic Surg Lasers Imaging</source>
            <year>2005</year>
            <season>Mar-Apr</season>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-6</page-range>
            <pub-id pub-id-type="pmid">15792321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jordan</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>J Dutton</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Ruptured Globe, Sympathetic Ophthalmia, and the 14-Day Rule.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <string-date>2022 Jul-Aug 01</string-date>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>315</fpage>
            <page-range>315-324</page-range>
            <pub-id pub-id-type="pmid">34593714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic ophthalmia: a case report and review of the need for prophylactic enucleation.</article-title>
            <source>Can J Ophthalmol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-8</page-range>
            <pub-id pub-id-type="pmid">10321321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bilyk</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Enucleation, evisceration, and sympathetic ophthalmia.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2000</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>372</fpage>
            <page-range>372-86</page-range>
            <pub-id pub-id-type="pmid">11148706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brackup</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Nerad</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Folk</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Pulido</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of severely injured eyes following globe rupture.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <year>1991</year>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>194</fpage>
            <page-range>194-7</page-range>
            <pub-id pub-id-type="pmid">1911526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andreoli</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Kloek</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Andreoli</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Enucleation for open globe injury.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>147</volume>
            <issue>4</issue>
            <fpage>595</fpage>
            <page-range>595-600.e1</page-range>
            <pub-id pub-id-type="pmid">19181305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pieramici</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sternberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aaberg</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Bridges</surname>
                <given-names>WZ</given-names>
              </name>
              <name>
                <surname>Capone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cardillo</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>de Juan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meredith</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Mieler</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Rubsamen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stout</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A system for classifying mechanical injuries of the eye (globe). The Ocular Trauma Classification Group.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>123</volume>
            <issue>6</issue>
            <fpage>820</fpage>
            <page-range>820-31</page-range>
            <pub-id pub-id-type="pmid">9535627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McBain</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Ezra</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>SP</given-names>
              </name>
              <collab>Appearance Research Collaboration (ARC)</collab>
            </person-group>
            <article-title>The psychosocial impact of living with an ocular prosthesis.</article-title>
            <source>Orbit</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-44</page-range>
            <pub-id pub-id-type="pmid">24205995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Maumenee</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic uveitis following evisceration.</article-title>
            <source>Trans Am Acad Ophthalmol Otolaryngol</source>
            <year>1972</year>
            <season>May-Jun</season>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>625</fpage>
            <page-range>625-44</page-range>
            <pub-id pub-id-type="pmid">4667676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Roberge</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Whitcup</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>32 cases of sympathetic ophthalmia. A retrospective study at the National Eye Institute, Bethesda, Md., from 1982 to 1992.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1995</year>
            <month>May</month>
            <volume>113</volume>
            <issue>5</issue>
            <fpage>597</fpage>
            <page-range>597-600</page-range>
            <pub-id pub-id-type="pmid">7748129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic Ophthalmia: Experience from a Tertiary Care Center in Northern India.</article-title>
            <source>J Ophthalmic Vis Res</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>439</fpage>
            <page-range>439-446</page-range>
            <pub-id pub-id-type="pmid">30479714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dogra</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Reversible retinal changes in the acute stage of sympathetic ophthalmia seen on spectral domain optical coherence tomography.</article-title>
            <source>Int Ophthalmol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-10</page-range>
            <pub-id pub-id-type="pmid">21331811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Madeira</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Falc&#x000e3;o-Reis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Figueira</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant - A Case Report.</article-title>
            <source>Ophthalmol Ther</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>635</fpage>
            <page-range>635-641</page-range>
            <pub-id pub-id-type="pmid">31506865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wocker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Januschowski</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>[Steroid implant in treatment of sympathetic ophthalmia : Intravitreal implant of dexamethasone in cystoid macular edema in the context of sympathetic ophthalmia].</article-title>
            <source>Ophthalmologe</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>116</volume>
            <issue>4</issue>
            <fpage>380</fpage>
            <page-range>380-383</page-range>
            <pub-id pub-id-type="pmid">29948149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansour</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Dexamethasone Implant as Sole Therapy in Sympathetic Ophthalmia.</article-title>
            <source>Case Rep Ophthalmol</source>
            <year>2018</year>
            <season>May-Aug</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-263</page-range>
            <pub-id pub-id-type="pmid">29928220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riza</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ugarte-Gil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alisjahbana</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van de Vijver</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Panduru</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ruslami</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aarnoutse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Critchley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>van Crevel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical management of concurrent diabetes and tuberculosis and the implications for patient services.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>9</issue>
            <fpage>740</fpage>
            <page-range>740-53</page-range>
            <pub-id pub-id-type="pmid">25194887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Doan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khosla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McCluskey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Sangwan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sawhney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tyagi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Systemic immunosuppressive therapies for uveitis in developing countries.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>68</volume>
            <issue>9</issue>
            <fpage>1852</fpage>
            <page-range>1852-1862</page-range>
            <pub-id pub-id-type="pmid">32823402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ka&#x000e7;maz</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Kempen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Newcomb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gangaputra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Suhler</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Jabs</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Levy-Clarke</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Cyclosporine for ocular inflammatory diseases.</article-title>
            <source>Ophthalmology</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>576</fpage>
            <page-range>576-84</page-range>
            <pub-id pub-id-type="pmid">20031223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kothari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anesi</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Vitale</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Metzinger</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cer&#x000f3;n</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-17</page-range>
            <pub-id pub-id-type="pmid">26164736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Dodds</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Echandi</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Couto</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schlaen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tessler</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Long-term, drug-free remission of sympathetic ophthalmia with high-dose, short-term chlorambucil therapy.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>121</volume>
            <issue>2</issue>
            <fpage>596</fpage>
            <page-range>596-602</page-range>
            <pub-id pub-id-type="pmid">24572676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <collab>Standardization of Uveitis Nomenclature (SUN) Working Group</collab>
            <article-title>Classification Criteria for Vogt-Koyanagi-Harada Disease.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>228</volume>
            <fpage>205</fpage>
            <page-range>205-211</page-range>
            <pub-id pub-id-type="pmid">33845018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kijlstra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.</article-title>
            <source>Ophthalmology</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>126</volume>
            <issue>9</issue>
            <fpage>1297</fpage>
            <page-range>1297-1305</page-range>
            <pub-id pub-id-type="pmid">30959067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r109">
          <label>109</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Stern</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Nataneli</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <chapter-title>Vogt-Koyanagi-Harada Syndrome</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">34662085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tuberculous choroiditis masquerading as sympathetic ophthalmia: a case report.</article-title>
            <source>Intractable Rare Dis Res</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-174</page-range>
            <pub-id pub-id-type="pmid">32844076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rua</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pohlmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pleyer</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Sympathetic Ophthalmia - a Contribution to Immunology, Clinic and Current Imaging.</article-title>
            <source>Klin Monbl Augenheilkd</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>237</volume>
            <issue>9</issue>
            <fpage>1060</fpage>
            <page-range>1060-1069</page-range>
            <pub-id pub-id-type="pmid">32967030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patil</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rajguru</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sirsalmath</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bevinakatti</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Vogt-Koyanagi-Harada (VKH) syndrome: A new perspective for healthcare professionals.</article-title>
            <source>J Family Med Prim Care</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-35</page-range>
            <pub-id pub-id-type="pmid">32110561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Judson</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Granulomatous Sarcoidosis Mimics.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>680989</fpage>
            <pub-id pub-id-type="pmid">34307411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r114">
          <label>114</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Simakurthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Primary Intraocular Lymphoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35015415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Infectious Uveitis.</article-title>
            <source>Curr Ophthalmol Rep</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>170</fpage>
            <page-range>170-183</page-range>
            <pub-id pub-id-type="pmid">26618074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nair</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Moots</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Behcet's disease.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-77</page-range>
            <pub-id pub-id-type="pmid">28148585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalogeropoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sakkas</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vartholomatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Malamos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sreekantam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanavaros</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kalogeropoulos</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches.</article-title>
            <source>Int Ophthalmol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>295</fpage>
            <page-range>295-321</page-range>
            <pub-id pub-id-type="pmid">34370174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tomaiuolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iacob</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Neerukonda</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stagner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sajjadi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Ordo&#x000f1;ez Armijos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hyman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Milman</surname>
                <given-names>T</given-names>
              </name>
              <collab>IRIS Registry Analytic Center Consortium</collab>
            </person-group>
            <article-title>Sympathetic Ophthalmia in Patients with Enucleation or Evisceration: Pathology Laboratory and IRIS<sup>&#x000ae;</sup> Registry Experience.</article-title>
            <source>Ocul Oncol Pathol</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>5-6</issue>
            <fpage>138</fpage>
            <page-range>138-151</page-range>
            <pub-id pub-id-type="pmid">38089175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agrawal</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sangwan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Current approach in diagnosis and management of anterior uveitis.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2010</year>
            <season>Jan-Feb</season>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-9</page-range>
            <pub-id pub-id-type="pmid">20029142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harthan</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Opitz</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Fromstein</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Morettin</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of anterior uveitis: optometric management.</article-title>
            <source>Clin Optom (Auckl)</source>
            <year>2016</year>
            <volume>8</volume>
            <fpage>23</fpage>
            <page-range>23-35</page-range>
            <pub-id pub-id-type="pmid">30214346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caspi</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>A look at autoimmunity and inflammation in the eye.</article-title>
            <source>J Clin Invest</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>120</volume>
            <issue>9</issue>
            <fpage>3073</fpage>
            <page-range>3073-83</page-range>
            <pub-id pub-id-type="pmid">20811163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baheti</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Siddique</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Cataract surgery in patients with history of uveitis.</article-title>
            <source>Saudi J Ophthalmol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-60</page-range>
            <pub-id pub-id-type="pmid">23960969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonneveld</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Management of multiple myeloma in the relapsed/refractory patient.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2017</year>
            <month>Dec</month>
            <day>08</day>
            <volume>2017</volume>
            <issue>1</issue>
            <fpage>508</fpage>
            <page-range>508-517</page-range>
            <pub-id pub-id-type="pmid">29222299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lohiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhaniwala</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dudhekar</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>A Comprehensive Review of Treatment Strategies for Early Avascular Necrosis.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>e50510</fpage>
            <pub-id pub-id-type="pmid">38226130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r125">
          <label>125</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sendrasoa</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Ranaivo</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Raherivelo</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Rapelanoro Rabenja</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ramarozatovo</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Adverse Effects of Long-Term Oral Corticosteroids in the Department of Dermatology, Antananarivo, Madagascar.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>1337</fpage>
            <page-range>1337-1341</page-range>
            <pub-id pub-id-type="pmid">34594123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r126">
          <label>126</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conway</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Risk of liver disease in methotrexate treated patients.</article-title>
            <source>World J Hepatol</source>
            <year>2017</year>
            <month>Sep</month>
            <day>18</day>
            <volume>9</volume>
            <issue>26</issue>
            <fpage>1092</fpage>
            <page-range>1092-1100</page-range>
            <pub-id pub-id-type="pmid">28989565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r127">
          <label>127</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miossec</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor.</article-title>
            <source>Cell Mol Immunol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>1644</fpage>
            <page-range>1644-1651</page-range>
            <pub-id pub-id-type="pmid">34021269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r128">
          <label>128</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warburton</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Nicol</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Bredin</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Health benefits of physical activity: the evidence.</article-title>
            <source>CMAJ</source>
            <year>2006</year>
            <month>Mar</month>
            <day>14</day>
            <volume>174</volume>
            <issue>6</issue>
            <fpage>801</fpage>
            <page-range>801-9</page-range>
            <pub-id pub-id-type="pmid">16534088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r129">
          <label>129</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jimmy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jose</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Patient medication adherence: measures in daily practice.</article-title>
            <source>Oman Med J</source>
            <year>2011</year>
            <month>May</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>155</fpage>
            <page-range>155-9</page-range>
            <pub-id pub-id-type="pmid">22043406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r130">
          <label>130</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messmer</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benitez Del Castillo</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mrukwa-Kominek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rolando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vitovska</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Baudouin</surname>
                <given-names>C</given-names>
              </name>
              <collab>a panel of European dry eye disease experts</collab>
            </person-group>
            <article-title>Management of inflammation in dry eye disease: Recommendations from a European panel of experts.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2023</year>
            <month>May</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>1294</fpage>
            <page-range>1294-1307</page-range>
            <pub-id pub-id-type="pmid">36471573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r131">
          <label>131</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pahwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Chronic Inflammation</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">29630225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r132">
          <label>132</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dutt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tabuena</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ventura</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rostami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shindler</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Timing of corticosteroid therapy is critical to prevent retinal ganglion cell loss in experimental optic neuritis.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>1439</fpage>
            <page-range>1439-45</page-range>
            <pub-id pub-id-type="pmid">19892867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r133">
          <label>133</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vijaya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manish</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ronnie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shantha</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Management of complications in glaucoma surgery.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>59 Suppl</volume>
            <issue>Suppl1</issue>
            <fpage>S131</fpage>
            <page-range>S131-40</page-range>
            <pub-id pub-id-type="pmid">21150025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r134">
          <label>134</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bodaghi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Khoramnia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pavesio</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2&#x02009;&#x003bc;g/day fluocinolone acetonide intravitreal implant (ILUVIEN<sup>&#x000ae;</sup>).</article-title>
            <source>J Ophthalmic Inflamm Infect</source>
            <year>2020</year>
            <month>Nov</month>
            <day>30</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">33251553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r135">
          <label>135</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganesh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Sundaram</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Babu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cataract surgery in sympathetic ophthalmia.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>11</issue>
            <fpage>2371</fpage>
            <page-range>2371-6</page-range>
            <pub-id pub-id-type="pmid">15519091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r136">
          <label>136</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalogeropoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>VC</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of Uveitic Glaucoma.</article-title>
            <source>J Curr Glaucoma Pract</source>
            <year>2018</year>
            <season>Sep-Dec</season>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>125</fpage>
            <page-range>125-138</page-range>
            <pub-id pub-id-type="pmid">31354205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r137">
          <label>137</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saat&#x000e7;i</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Ayhan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>&#x00130;pek</surname>
                <given-names>&#x0015e;C</given-names>
              </name>
              <name>
                <surname>S&#x000f6;ylev Bajin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal Aflibercept as an Adjunct to Systemic Therapy in a Case of Choroidal Neovascular Membrane Associated with Sympathetic Ophthalmia.</article-title>
            <source>Turk J Ophthalmol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>209</fpage>
            <page-range>209-211</page-range>
            <pub-id pub-id-type="pmid">30202619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r138">
          <label>138</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Do motivational cards really benefit sibling screening of primary open-angle glaucoma probands?</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>12</issue>
            <fpage>4158</fpage>
            <page-range>4158-4163</page-range>
            <pub-id pub-id-type="pmid">36453305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r139">
          <label>139</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurnani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Nayak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Balakrishnan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Parkash</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Morya</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Porwal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pediatric corneal transplantation: techniques, challenges, and outcomes.</article-title>
            <source>Ther Adv Ophthalmol</source>
            <year>2024</year>
            <season>Jan-Dec</season>
            <volume>16</volume>
            <fpage>25158414241237906</fpage>
            <pub-id pub-id-type="pmid">38533487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r140">
          <label>140</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nascimento</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yasuta</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Marquezan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Salom&#x000e3;o</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Francesconi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Muccioli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Belfort</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Uveitic band keratopathy: child and adult.</article-title>
            <source>J Ophthalmic Inflamm Infect</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <pub-id pub-id-type="pmid">26590046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r141">
          <label>141</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohammadpour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Elyasi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vahdati</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mohammadpour</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Shamsara</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A review on therapeutic drug monitoring of immunosuppressant drugs.</article-title>
            <source>Iran J Basic Med Sci</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>485</fpage>
            <page-range>485-98</page-range>
            <pub-id pub-id-type="pmid">23493821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r142">
          <label>142</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagner</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Dorairaj</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Updates on the Diagnosis and Management of Glaucoma.</article-title>
            <source>Mayo Clin Proc Innov Qual Outcomes</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>618</fpage>
            <page-range>618-635</page-range>
            <pub-id pub-id-type="pmid">36405987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r143">
          <label>143</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tripathi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Current Modalities for Low Vision Rehabilitation.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>e16561</fpage>
            <pub-id pub-id-type="pmid">34466307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r144">
          <label>144</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Nispen</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoeben</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Langelaan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klevering</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Keunen</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>van Rens</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Low vision rehabilitation for better quality of life in visually impaired adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Jan</month>
            <day>27</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD006543</fpage>
            <pub-id pub-id-type="pmid">31985055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r145">
          <label>145</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaharia</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Dumitrescu</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Radu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rogoz</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Adherence to Therapy in Glaucoma Treatment-A Review.</article-title>
            <source>J Pers Med</source>
            <year>2022</year>
            <month>Mar</month>
            <day>22</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35455630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r146">
          <label>146</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawrenson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Downie</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Nutrition and Eye Health.</article-title>
            <source>Nutrients</source>
            <year>2019</year>
            <month>Sep</month>
            <day>06</day>
            <volume>11</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31489894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r147">
          <label>147</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Dick</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>The Eyes Have it: A Rheumatologist's View of Uveitis.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>70</volume>
            <issue>10</issue>
            <fpage>1533</fpage>
            <page-range>1533-1543</page-range>
            <pub-id pub-id-type="pmid">29790291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r148">
          <label>148</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x00131;l&#x00131;&#x000e7;&#x000e7;&#x00131;o&#x0011f;lu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oncel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Celebi</surname>
                <given-names>ARC</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Disease-Related Dry Eye Diseases and Their Placement Under the Revised Classification Systems: An Update.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>e50276</fpage>
            <pub-id pub-id-type="pmid">38196419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r149">
          <label>149</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aremu</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Oluwole</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Adeyinka</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Schommer</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Medication Adherence and Compliance: Recipe for Improving Patient Outcomes.</article-title>
            <source>Pharmacy (Basel)</source>
            <year>2022</year>
            <month>Aug</month>
            <day>28</day>
            <volume>10</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">36136839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r150">
          <label>150</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lustberg</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kuderer</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bergerot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship.</article-title>
            <source>Nat Rev Clin Oncol</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>527</fpage>
            <page-range>527-542</page-range>
            <pub-id pub-id-type="pmid">37231127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r151">
          <label>151</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benavent</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Luque</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>N&#x000fa;&#x000f1;ez-Benjumea</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Navarro-Comp&#x000e1;n</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sanz-Jard&#x000f3;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Novella-Navarro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Sanz</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Calvo-Aranda</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lojo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Balsa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Plasencia-Rodr&#x000ed;guez</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Monitoring chronic inflammatory musculoskeletal diseases mixing virtual and face-to-face assessments-Results of the digireuma study.</article-title>
            <source>PLOS Digit Health</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>12</issue>
            <fpage>e0000157</fpage>
            <pub-id pub-id-type="pmid">36812651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r152">
          <label>152</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almazroa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Almatar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alduhayan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Albalawi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alghamdi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alhoshan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alamri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alkanhal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alsiwat</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Alrabiah</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aldrgham</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>AlSaleh</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alsanad</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Alsomaie</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The Patients' Perspective for the Impact of Late Detection of Ocular Diseases on Quality of Life: A Cross-Sectional Study.</article-title>
            <source>Clin Optom (Auckl)</source>
            <year>2023</year>
            <volume>15</volume>
            <fpage>191</fpage>
            <page-range>191-204</page-range>
            <pub-id pub-id-type="pmid">37719025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r153">
          <label>153</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kvarnstr&#x000f6;m</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Westerholm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Airaksinen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liira</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Factors Contributing to Medication Adherence in Patients with a Chronic Condition: A Scoping Review of Qualitative Research.</article-title>
            <source>Pharmaceutics</source>
            <year>2021</year>
            <month>Jul</month>
            <day>20</day>
            <volume>13</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">34371791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r154">
          <label>154</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donabedian</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Evaluating the quality of medical care. 1966.</article-title>
            <source>Milbank Q</source>
            <year>2005</year>
            <volume>83</volume>
            <issue>4</issue>
            <fpage>691</fpage>
            <page-range>691-729</page-range>
            <pub-id pub-id-type="pmid">16279964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r155">
          <label>155</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pacholczak-Madej</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kosa&#x00142;ka-W&#x00119;giel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuszmiersz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mitu&#x0015b;</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>P&#x000fc;sk&#x000fc;ll&#x000fc;o&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grela-Wojewoda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Korkosz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bazan-Socha</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2023</year>
            <month>Mar</month>
            <day>10</day>
            <volume>20</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">36981837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r156">
          <label>156</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mardani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaismoradi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Role of the Nurse in the Management of Medicines During Transitional Care: A Systematic Review.</article-title>
            <source>J Multidiscip Healthc</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>1347</fpage>
            <page-range>1347-1361</page-range>
            <pub-id pub-id-type="pmid">33154651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r157">
          <label>157</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schnipper</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kirwin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cotugno</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Wahlstrom</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Tarvin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kachalia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Horng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>McKean</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Role of pharmacist counseling in preventing adverse drug events after hospitalization.</article-title>
            <source>Arch Intern Med</source>
            <year>2006</year>
            <month>Mar</month>
            <day>13</day>
            <volume>166</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-71</page-range>
            <pub-id pub-id-type="pmid">16534045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r158">
          <label>158</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shah</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thornton</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Turrin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hipskind</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <chapter-title>Informed Consent</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">28613577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r159">
          <label>159</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dehghani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghomian</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rakhshanderou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khankeh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kavousi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Process and components of disaster risk communication in health systems: A thematic analysis.</article-title>
            <source>Jamba</source>
            <year>2022</year>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>1367</fpage>
            <pub-id pub-id-type="pmid">36569774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-151525.r160">
          <label>160</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rodziewicz</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Houseman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vaqar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hipskind</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <chapter-title>Medical Error Reduction and Prevention</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29763131</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
